2,4,6-triamino-1,3,5-triazine derivative

ABSTRACT

This invention relates to an anti-dementia agent which uses a BEC 1 potassium channel inhibitor as the active ingredient. 
     It was proved that the BEC 1 potassium channel inhibitor has an action to improve learning disorder and is useful as a preventive or therapeutic agent for diseases, preferably dementia, in which the BEC 1 potassium channel is considered to be concerned. 
     Illustratively, it was confirmed by an in vivo test that the BEC 1 potassium channel inhibitor has an action to improve learning disorder. 
     Also, it was found that a compound having 2,4,6-triamino-1,3,5-triazine has a BEC 1 potassium channel inhibitory action.

This is a divisional of application Ser. No. 10/503,494 filed Aug. 5, 2004, which is a National Stage application of PCT Application No. PCT/JP03/01065, filed Feb. 3, 2003, which claims priority of Japanese Application No. JP 2002-28844, filed Feb. 5, 2002, the disclosure of each of which is incorporated herein by reference in its entirety

TECHNICAL FIELD

This invention relates to medicaments, particularly an anti-dementia agent which comprises a substance having BEC 1 potassium channel inhibitory action as the active ingredient, preferably an anti-dementia agent wherein the substance having BEC 1 potassium channel inhibitory action is a 2,4,6-triamino-1,3,5-triazine derivative or a pharmaceutically acceptable salt thereof, and a novel 2,4,6-triamino-1,3,5-triazine derivative or a pharmaceutically acceptable salt thereof.

BACKGROUND OF THE INVENTION

Potassium channel is a protein which distributes in the plasma membrane of cells and lets potassium ions selectively pass trough it and is considered to be taking an important role in controlling membrane potential of cells. Particularly, this is contributing to the neurotransmission of central and peripheral nerves, pace-making of the heart, contraction of muscles and the like by regulating frequency, persistency and the like of action potential in nerve and muscle cells.

As the classification based on the opening and closing mechanism of the channel, a voltage-dependent potassium channel, an inwardly rectifying potassium channel, a calcium-dependent potassium channel, a receptor coupling type potassium channel and the like have so far been identified. Among them, the voltage-dependent potassium channel has a property to open it when the membrane potential is depolarized. In general, potassium ions are present in a non-equilibrium state of about 5 mM in the extracellular moiety and about 150 mM in the intracellular moiety. Accordingly, when the voltage-dependent potassium channel is opened due to depolarization, potassium ions flow out from the intracellular part into the extracellular part and cause restoration (re-polarization) of membrane potential as a result. Thus, reduction of excitability of nerve and muscle calls is induced accompanied by the opening of the voltage-dependent channel [Non-patent reference 1].

Compounds capable of modifying opening of the voltage-dependent channel have a possibility to regulate various physiological phenomena by regulating excitability of nerve and muscle cells and therefore to become therapeutic drugs of various diseases.

For example, it is known that 4-aminopyridine which is an inhibitor of the A type voltage-dependent potassium channel found in nerve cells causes epilepsy by increasing excitability of nerves [Non-patent reference 3]. In addition, dofetilide which is an inhibitor of HERG potassium channel expressing in the heart, among voltage-dependent potassium channels, is used as an agent for treating arrhythmia based on its property to control excitability of cardiac muscle cells [Non-patent reference 4].

The potassium channel described as SEQ ID NO:2 in Example 1 of U.S. Pat. No. 6,326,168 (corresponding international patent publication pamphlet WO 99/37677) [Patent reference 1] (to be referred to as BEC 1 or BEC 1 potassium channel hereinafter) is a voltage-dependent potassium channel which shows an expression distribution localized to the brain. Its expression is significant particularly in the hippocampus and cerebral cortex. The hippocampus is a region whose relation to memory and learning are strongly suggested [Non-patent reference 5].

Particularly, granule cells of dentate gyrus and CA 1 and CA 3 pyramidal cells wherein BEC 1 potassium channel expresses form a neural circuit, and input of various memories is transmitted from the granule cells of dentate gyrus to the CA 3 pyramidal cell through the CA 1 pyramidal cell, via an excitatory synapse which uses glutamic acid as the neurotransmitter. It is considered that long-term changes in the long-term potentiation, long-term depression and the like synaptic transmission efficiencies found in respective synapses are deeply concerned in the memory and learning. These long-term changes are regulated by the excitation frequency and excitation strength of nerve cells. In addition, the voltage-dependent potassium channel generally has a possibility of being able to control excitability of nerve cells.

Accordingly, it is considered that BEC 1 is concerned in the formation of memory and learning via the excitability control of nerve cells, but this has not been illustratively proved.

A large number of 2,4,6-triamino-1,3,5-triazine derivatives are currently known, and their uses are disclosed as an anti-HIV agent [Non-patent reference 6], an adenosine A 3 antagonist [Patent reference 2], and antimicrobial agents [Non-patent reference 7], [Non-patent reference 8], [Non-patent reference 9] and [Patent reference 3]. Though many potassium channel inhibitors and 2,4,6-triamino-1,3,5-triazine derivatives have so far been reported [Patent reference 3] and [Non-patent reference 10], there are no reports or suggestions stating that they have BEC 1 potassium channel inhibitory action.

The object of the invention is to provide an anti-dementia agent which uses a substance having BEC 1 potassium channel inhibitory action (to be referred to as BEC 1 potassium channel inhibitor hereinafter) as the active ingredient, preferably an anti-dementia agent wherein the BEC 1 potassium channel inhibitor is a 2,4,6-triamino-1,3,5-triazine derivative or a pharmaceutically acceptable salt thereof, a novel 2,4,6-triamino-1,3,5-triazine derivative having BEC 1 potassium channel inhibitory action or a pharmaceutically acceptable salt thereof, and a medicament comprising said novel derivative or a pharmaceutically acceptable salt thereof.

The present inventors have conducted studies with the aim of achieving the above object and found as a result that a BEC 1 potassium channel inhibitor can become an anti-dementia agent. In addition, it was found unexpectedly that a compound having the 2,4,6-triamino-1,3,5-triazine structure has a BEC 1 potassium channel inhibitory action, thus resulting in the accomplishment of the invention.

[Non-Patent Reference 1]

-   Hille, B. (ed), Ionic Channels of Excitable Membranes (Sinauer     Associates, Sunderland, 1992)

[Non-Patent Reference 2]

-   Catterall, W. A., Chandy, K. G. & Gutman G. A. (eds), The IUPHAR     Compendium of Voltage-gated Ion Channels (IUPHAR Media, Leeds, UK,     2002)

[Non-Patent Reference 3]

-   Yamaguchi, S, and Rogawski, M. A., Epilepsy Res., 11: 9-16 (1992)

[Non-Patent Reference 4]

-   Gwilt, M., Arrowsmith, J. E., Blackburn, K. J., Burges, R. A.,     Cross, P. E., Dalrymple, H. W. and Higgins, A. J., J. Pharmacol.     Exp. Ther., 256: 318-324 (1991)

[Non-Patent Reference 5]

-   Levitan, I. B. and Kaczmarek L. K. (1991), The Neuron: Cell and     Molecular Biology, Oxford University Press, New York, N.Y.

[Non-Patent Reference 6]

-   Bioorg. Med. Chem. Lett., (2001) 11, 2229-2234

[Non-Patent Reference 7]

-   Acta Cienc. Indica. Chem., (1992) 18(4), 405-406

[Non-Patent Reference 8]

-   Acta Cienc. Indica. Chem., (1985) 11(1), 66-70

[Non-Patent Reference 9]

-   J. Indian Chemical Society, (1987) 64(12), 770-771

[Non-Patent Reference 10]

-   J. Inst. Chem. (India), (1987) 59(4), 183-185

[Patent Reference 1]

-   U.S. Pat. No. 6,326,168

[Patent Reference 2]

-   JP-A-11-158073

[Patent Reference 3]

-   International Publication Pamphlet WO 99/1442

DISCLOSURE OF THE INVENTION

The invention relates to an anti-dementia agent which comprises a substance having BEC 1 potassium channel inhibitory action as the active ingredient.

It is preferably an anti-dementia agent wherein the substance having BEC 1 potassium channel inhibitory action is a 2,4,6-triamino-1,3,5-triazine derivative represented by a formula (I) or a pharmaceutically acceptable salt thereof

(symbols in the formula are as follows

R¹ and R²: the same or different from each other, and each represents H, OH, an alkyl-O—, an aryl-CO—, H₂N, an alkyl-NH which may be substituted with OH, an (alkyl)₂N, a hydrocarbon radical which may be substituted or a hetero ring which may be substituted, or R¹, R² and the adjacent N may together form a nitrogen-containing hetero ring and said ring may be substituted,

R³, R⁴, R⁵ and R⁶: the same or different from one another, and each represents (i) H, (ii) CN, (iii) NO₂, (iv) a halogen, (v) a lower alkyl which may be substituted with (1) CN, (2) a halogen or (3) OH, (vi) a cycloalkyl, (vii) an aryl which may be substituted with a lower alkyl, (ix) a hetero ring which may be substituted with a lower alkyl, (x) R⁷R⁸N— (R⁷ and R⁸: the same or different from each other, and each represents (1) H or (2) a lower alkyl which may be substituted with an aryl or R⁹—O—CO— (R⁹: (1) H or a lower alkyl which may be substituted with an aryl), (xi) R¹⁰-T¹- (R¹⁰: (1) H, (2) a lower alkyl which may be substituted with an aryl, an HO—C₁₋₁₀ alkylene-O— or HO or (3) an aryl, T¹: O or S), or (xii) R¹¹-T²- (R¹¹: (1) OH, (2) R⁷R⁸N—, (3) a lower alkyl-O—, (4) a lower alkyl, (5) an aryl or (6) a hetero ring, (T²: CO or SO₂)),

further, R³, R⁴ and the adjacent C, or R⁵, R⁶ and the adjacent C, may together form a hetero ring or cyclic hydrocarbon ring, and the ring may be condensed with a benzene ring).

Another embodiment of the invention is BEC 1 potassium channel described as SEQ ID NO:2 inhibitor having a 2,4,6-triamino-1,3,5-triazine derivative represented by a formula (I) or a pharmaceutically acceptable salt thereof as an ingredient.

Also, another embodiment of the invention is a 2,4,6-triamino-1,3,5-triazine derivative represented by a formula (II) or a pharmaceutically acceptable salt thereof

(symbols in the formula are as follows

R¹ and R²: the same or different from each other, and each represents H, OH, an alkyl-O—, an aryl-CO—, H₂N, an alkyl-NH which may be substituted with OH, an (alkyl)₂N, a hydrocarbon radical which may be substituted or a hetero ring which may be substituted, or R¹, R² and the adjacent N may together form a nitrogen-containing hetero ring and said ring may be substituted,

R³, R⁴, R⁵ and R⁶: the same or different from one another, and each represents (i) H, (ii) CN, (iii) NO₂, (iv) a halogen, (v) a lower alkyl which may be substituted with (1) CN, (2) a halogen or (3) OH, (vi) a cycloalkyl, (vii) an aryl which may be substituted with a lower alkyl, (ix) a hetero ring which may be substituted with a lower alkyl, (x) R⁷R⁸N— (R⁷ and R⁸: the same or different from each other, and each represents (1) H or (2) a lower alkyl which may be substituted with an aryl or R⁹—O—CO— (R⁹: (1) H or a lower alkyl which may be substituted with an aryl), (xi) R¹⁰-T¹- (R¹⁰: (1) H, (2) a lower alkyl which may be substituted with an aryl, an HO—C₁₋₁₀ alkylene-O— or HO or (3) an aryl, T¹: O or S), or (xii) R¹¹-T²- (R¹¹: (1) OH, (2) R⁷R⁸N—, (3) a lower alkyl-O—, (4) a lower alkyl, (5) an aryl or (6) a hetero ring, (T²: CO or SO₂)),

further, R³, R⁴ and the adjacent C, or R⁵, R⁶ and the adjacent C, may together form a hetero ring or cyclic hydrocarbon ring, and the ring may be condensed with a benzene ring),

excluding a case in which R¹ and R² in the aforementioned formula (II) are the same or different from each other, and each represents (i) H, NH₂, a cyclohexyl, phenyl which may be substituted, R^(a)—(CH₂)₂— (R^(a): HS, HO, R⁷R⁸N, COOH, an ethoxy, CN, morpholino or chloro), an alkyl which may be substituted with a substituent group of the following (a) to (e) ((a), HOOC, (b) an alkyl-O—CO—, (c) phenyl which may be substituted, (d) R⁷R⁸NCONHCO or (e) R⁷R⁸NCONHCO—), an alkenyl, phenyl-S—, phenyl-SO₂—, phenyl-NHCS— which may be substituted, phenyl-NHCO— which may be substituted, an alkyl-O—CO—, H₂NCS, chloro-COCH₂— or 1,3,4-oxadiazol-2-ylmethyl which may be substituted, or R¹, R² and the adjacent C together form pyrazol-1-yl, indol-1-yl, indazol-2-yl, piperidin-1-yl or morpholin-4-yl and R³, R⁴, R⁵ and R⁶ are the same or different from one another and each represents H, a halogen, NO₂, acetyl, HO, a lower alkyl-O—, HOOC—, a lower alkyl-O—CO—, H₂NSO₂— or a lower alkyl; the same shall apply thereinafter).

Still another embodiment of the invention is a medicament which comprises the 2,4,6-triamino-1,3,5-triazine derivative described by the aforementioned formula (II) or a pharmaceutically acceptable salt thereof.

Preferred embodiment of the invention is a 2,4,6-triamino-1,3,5-triazine derivative or a pharmaceutically acceptable salt thereof having the following substituent groups in the formula (I) or formula (II);

(1) R¹ and R² are different from each other and are H and a hydrocarbon radical which may be substituted, and the hydrocarbon radical is more preferably an alkyl, further preferably a hetero ring-substituted alkyl which may be substituted,

(2) R¹ and R² are different from each other and are H and a hetero ring which may be substituted, and said hetero ring is more preferably a four- to six-membered single ring containing 1 or 2 hetero atoms selected from S and O,

(3) R³, R⁴, R⁵ and R⁶ are H,

(4) R³, R⁴, R⁵ and R⁶ are the same or different from one another and are H and a halogen,

(5) R³, R⁴, R⁵ and R⁶ are the same or different from one another and are H and a lower alkyl which may be substituted with [(1) a halogen or (2) OH],

(6) R³, R⁴, R⁵ and R⁶ are the same or different from one another and are H, a halogen and a lower alkyl which may be substituted with [(1) a halogen or (2) OH],

(7) R³, R⁴, R⁵ and R⁶ are the same or different from one another and are H and R¹⁰-T¹-, or

(8) R³, R⁴, R⁵ and R⁶ are the same or different from one another and are H, a halogen and R¹⁰-T¹-.

Particularly preferred is a 2,4,6-triamino-1,3,5-triazine derivative or a pharmaceutically acceptable salt thereof, having a combination of the aforementioned (1) or (2) with any one of (3) to (8).

Preferred compound is any one of the 2,4,6-triamino-1,3,5-triazine derivatives shown in the following table or a pharmaceutically acceptable salt thereof.

TABLE 1

(The numbers 2 to 6 in the formula above represent respective bonding positions of R³ and R⁵.)

R³ R⁵ Py-4-ylCH₂NH— H H Py-3-ylCH₂NH— H H Py-2-ylCH₂NH— H H 2-FPy-4-ylCH₂NH— H H 2-ClPy-4-ylCH₂NH— H H 2-iPrPy-4-ylCH₂NH— H H BzlNH— H H 4-FPhCH₂NH— H H Py-4-yl(CH₂)₂NH— H H 2-FPy-4-ylCH₂NH— H 3,4-diF 2-FPy-4-ylCH₂NH— H 4-MeO 2-FPy-4-ylCH₂NH— 4-Me 4-F

H H

H H

H H

H 4-Me Py-4-ylCH₂NH— 4-F 4-F Py-3-ylCH₂NH— 4-F 4-F Py-2-ylCH₂NH— 4-F 4-F BzlNH— 4-F 4-F 4-FPhCH₂NH— 4-F 4-F Py-4-yl(CH₂)₂NH— H H HCCCH₂NH— H H MeO(CH₂)₂NH— H H MeO(CH₂)₃NH— H H 2-FPy-4-ylCH₂NH— 4-F 4-F 2-FPy-4-ylCH₂NH— H 4-F 2-MePy-4-ylCH₂NH— H 4-F 2-FPy-4-ylCH₂NH— H 4-Me

H 4-F

H 4-F

H 4-F HCCCH₂NH— H H HO(CH₂)₄NH— H 4-F HO(CH₂)₅NH— H 4-F HO(CH₂)₂O(CH₂)₂NH— H 4-F MeS(CH₂)₃NH— H H HO(CH₂)₃NH— H H HO(CH₂)₅NH— H H HO(CH₂)₂O(CH₂)₂NH— H H 2-FPy-4-ylCH₂NH— 4-MeO 4-F 2-FPy-4-ylCH₂NH— 4-Cl 4-F 2-FPy-4-ylCH₂NH— H 4-Cl 2-FPy-4-ylCH₂NH— H 4-F

4-F 4-F

H H

H H

H 4-F (Symbols in the table are as follows. Ph; phenyl, Py; pyridine, Bzl; benzyl)

A further embodiment of the invention is a method for treating dementia, which comprises administering the aforementioned BEC 1 inhibitor to a patient.

A still further embodiment is a method for preparing a medicament, particularly a pharmaceutical composition for dementia treatment use, which comprises a compound obtained by a screening method in which a compound to be tested is allowed to contact with BEC 1 potassium channel-expressed cells to identify if it inhibits said channel activity.

The symbols used hereinafter have the same meanings.

The following further describes the compound represented by the general formula (I) or (II). Unless otherwise noted, the term “lower” as used in the definition of the general formula of this specification means a straight or branched carbon chain having from 1 to 6 carbon atoms.

As the “halogen”, fluorine, chlorine, bromine or iodine atom can be cited.

The “hydrocarbon radical” is a straight or branched chain hydrocarbon radical having from 1 to 15 carbon atoms, preferably from 1 to 10 carbon atoms, or a cyclic hydrocarbon radical having from 3 to 15 carbon atoms. The straight or branched chain hydrocarbon radical is an “alkyl”, an “alkenyl” or an “alkynyl”. Illustrative example of the “alkyl” is methyl, ethyl, isopropyl, hexyl, decyl, tetradecyl, pentadecyl or the like. The “alkenyl” is a hydrocarbon radical having at least one or more double bonds, such as vinyl, propenyl, allyl, isopropenyl, hexenyl or the like. The “alkynyl” is a hydrocarbon radical having at least one or more triple bonds, such as ethynyl, propynyl, butynyl or the like. The cyclic hydrocarbon radical is a “cycloalkyl”, a “cycloalkenyl” or an “aryl”. Illustrative example of the “cycloalkyl” is a monocyclic saturated ring such as cyclopropyl, cyclopentyl, cyclohexyl, cyclooctyl, cyclodecyl or the like. Said cycloalkyl may be bridged or condensed with benzene. For example, a C₃₋₁₀ cycloalkyl shown below is desirable. The “cycloalkenyl” is a hydrocarbon ring having one or more double bonds, and said cycloalkenyl may be condensed with a hetero ring, an aryl or a C₃₋₁₀ cycloalkyl. For example, a C₃₋₈ cycloalkenyl shown below is desirable. The “aryl” means an aromatic hydrocarbon radical including a C₆₋₁₄ aryl such as phenyl, naphthyl, anthryl or the like.

Said aryl may be condensed with a hetero ring, a C₃₋₁₀ cycloalkenyl, a C₃₋₁₀ cycloalkyl or a benzene-condensed cycloalkyl. For example, a di or tricyclic shown below is desirable.

Particularly, a di or tricyclic aryl condensed with benzene ring together with R³, R⁴ and the adjacent C, or R⁵, R⁶ and the adjacent C, may be substituted.

As said substituent group, oxo (═O), an aryl, an OH-aryl and a lower alkyl-O-aryl can be exemplified.

The “hetero ring” is a four- to seven-membered monocyclic, bicyclic or tricyclic aliphatic ring or aromatic ring containing from 1 to 4 hetero atoms selected from N, S and O. Said ring may be bridged or condensed with a C₃₋₁₀ cycloalkyl or a aryl. For example, the hetero rings shown in the following are preferred illustrative examples.

Regarding an aromatic nitrogen-containing hetero ring among the aforementioned hetero rings, a nitrogen atom on said ring may be quaternarized or form N-oxide.

The “nitrogen-containing hetero ring” is the aforementioned hetero ring having at least one nitrogen atom.

As the substituent group of the “hydrocarbon radical which may be substituted”, substituent groups of the group a described in the following can preferably be exemplified.

As the substituent group of the “hetero ring which may be substituted” and “nitrogen-containing hetero ring which can be formed by R¹ and R² together with the adjacent N”, substituent groups of the group a described in the following can preferably be exemplified.

Group a: (i) CN, (ii) NO₂, (iii) a halogen, (iv) R⁷R⁸N— (R⁷ and R⁸: the same or different from each other, and each represents (1) H, (2) a lower alkyl which may be substituted with an aryl or R⁹—O—CO— (R⁹: (1) H or a lower alkyl which may be substituted with an aryl), (3) an aryl which may be substituted with CN or a lower alkyl, (4) a hetero ring, (5) a lower alkyl-CO—, (6) a lower alkyl-O—CO—. (7) a cycloalkyl which may be substituted with HS— or a lower alkyl-S—, (8) an aryl-SO₂— which may be substituted with NO₂ or (9) a hetero ring-SO₂—), (v) R¹⁰-T¹- (R¹⁰: (1) H, (2) a lower alkyl which may be substituted with an aryl, an HO—C₁₋₁₀ alkylene-O— or HO or (3) an aryl, T¹: 0 or S), (vi) R¹¹-T²- (R¹¹: (1) OH, (2) R⁷R⁸N—, (3) a lower alkyl-O—, (4) a lower alkyl, (5) an aryl or (6) a hetero ring (T²: CO or SO₂)), (vii) a lower alkyl which may be substituted with a substituent group among the following (1) to (6) ((1) a halogen, (2) CN, (3) OH, (4) R¹⁰CO—, (5) R⁷R⁸N— or (6) an aryl), (viii) a cycloalkyl which may be substituted with a lower alkyl, (ix) a cycloalkenyl, (x) a cycloalkynyl, (xi) an aryl which may be substituted with a substituent group among the following (1) to (5) ((1) a halogen, (2) NO₂, (3) R¹²-T¹- (R¹²: R¹⁰ or a lower alkyl-aryl which may be substituted with OH, (4) H₂NO₂S— or (5) a lower alkyl which may be substituted with a halogen or OH), or (xii) a hetero ring which may be substituted with a substituent group among the following (1) to (9) ((1) a halogen, (2) oxo (═O), (3) NO₂, (4) a lower alkyl which may be substituted with [R⁷R⁸N—, R¹⁰-T¹-, an aryl which may be substituted with (OH, a halogen or a lower alkyl-O—), (5) an aryl which may be substituted with a halogen, (6) OH, (7) a lower alkyl-O—, (8) R⁷R⁸N—, or (9) a hetero ring,

The “BEC 1” and “BEC 1 potassium channel” mean the complete length protein represented by SEQ ID NO:2, or a fragment of said protein having the same function of said protein, or a fragment or complete length protein of said protein in which one or more amino acids may be substituted, deleted or inserted.

The “substance having BEC 1 potassium channel inhibitory action” can be obtained by subjecting compounds to be tested to a typical screening method such as the method described in U.S. Pat. No. 6,326,168.

a) Screening Method which Uses Voltage-Clump Method

It is possible to measure channel activity of the BEC 1 potassium channel protein by the whole-cell voltage-clamp method. Cells expressing this channel protein are voltage-clamped and whole-cell current is recorded by the whole-cell voltage-clamp method. For example, a solution containing 145 mM NaCl, 5.4 mM KCl, 2 mM CaCl₂ and 0.8 mM MgCl₂ is used as the extracellular solution, and a solution containing 155 mM KCl is used as the intracellular solution (patch electrode solution). A compound and a peptide capable of modifying activity of the BEC 1 potassium channel protein can be screened by comparing outward currents generated by a depolarization stimulus, namely shifting a membrane potential from a holding potential (e.g., −70 mV) to a depolarization side (e.g., −80 mV), in the presence and absence of each drug to be tested.

b) Screening Method which Uses Release of Rb⁺ Ion

In general, the potassium channel can pass Rb⁺ ion similar to K⁺ ion, so that the channel activity can be measured using release of a radioisotope ⁸⁶Rb⁺ as a marker. By incubating cells expressing the novel potassium channel protein together with ⁸⁶RbCl (e.g., 18 hr, 37° C.), ⁸⁶Rb⁺ can be incorporated into the cells. The cells are washed with a low K⁺ concentration physiological saline (e.g., 4.5 mM K⁺) and then suspended in the same solution. When a high K⁺ concentration solution (e.g., 100 mM in final concentration) is added to the cell suspension, membrane potential of the cell is depolarized and the potassium channel therefore is activated. As a result, the intracellular ⁸⁶Rb⁺ is released into the extracellular part, thus radioactivity of the extracellular solution can be used as a marker of the channel activity. It is possible to screen a compound and a peptide capable of modifying activity of the BEC 1 potassium channel protein, by comparing the radioactivity released into the extracellular part when the high K⁺ concentration solution is added in the presence and absence of each drug to be tested.

c) Screening Method which Uses a Voltage-Sensitive Dye or a Intracellular K⁺-Detecting Dye

It is possible that a voltage-sensitive dye or a intracellular K⁺-detecting dye can optically detect a change in the potential or intracellular K⁺ concentration accompanied by the opening of potassium channel. As the voltage-sensitive dye, RH 155, WW 781, Di-4-ANEPPS, derivatives thereof and the like can be used. In addition, a chimeric protein in which the amino acid sequence of green fluorescent protein is inserted into the C-terminal intracellular region of a Shaker type membrane voltage-dependent potassium channel can also be used in the detection of membrane potential (Siegel, M. S. and Isacoff, E. Y. (1997), Neuron, 19, 735-741). As the intracellular K⁺-detecting dye, K⁺-binding benzofuran isophthalate and the like can be used. By the use of these dyes, channel activity of the BEC 1 potassium channel can be measured and it is possible to screen a compound and a peptide capable of modifying activity of the BEC 1 potassium channel protein by comparing their changing amounts in the presence and absence of a drug to be tested.

Preferred screening method is a method for measuring BEC 1 inhibitory activity of a compound using ⁸⁶Rb ion releasing amount as the index, which is described later.

In addition, by allowing the Example 13 as a typical compound of the invention and a compound to be tested to undergo competitive BEC 1 potassium channel inhibition, a substance having said action can be obtained.

The compound to be tested may be illustratively any substance which has said inhibitory activity, and its examples include known compounds commercially available or registered in chemical file, a group of compounds obtained by combinatorial chemistry techniques, culture supernatants of microorganisms, natural components derived from plants and marine organisms, animal tissue extracts, antibodies and dominant negative proteins and the like. Also included are those in which said substances are modified with a substituent group or the like by a chemical conversion as a conventional method for those skilled in the art.

Depending on the type of groups, optical isomers (optically active substances, diastereomers and the like) are present in the compounds of the invention. Since compounds having amide bond and double bond are present in the compounds of the invention, tautomers based on the amide bond and geometrical isomers are also present. Separated or mixed forms of these isomers are included in the invention.

The compound of the invention forms a salt with an acid or a base. Examples of the salt with an acid include acid addition salts with inorganic acid such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid and the like mineral acids, and with organic acids such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, citric acid, tartaric acid, carbonic acid, picric acid, methanesulfonic acid, ethanesulfonic acid, glutamic acid and the like.

Examples of the salt with a base include salts with sodium, potassium, magnesium, calcium, aluminum and the like inorganic bases, methylamine, ethylamine, meglumine, ethanolamine and the like organic bases, or lysine, arginine, ornithine and the like basic amino acids, as well as an ammonium salt. Also, the compound of the invention can form a hydrate, solvates with ethanol and the like and polymorphism.

In addition, all of the compounds which are metabolized and converted in the living body, so-called prodrugs, are also included in the active ingredient of the invention or compound of the invention. Examples of the group which forms the prodrug of the invention include the groups described in Prog. Med., 5, 2157-2161 (1985) and “Iyakuhin-no Kaihatsu (Development of Medicaments”, Vol. 7 (Hirokawa Shoten, 1990), Bunshi Sekkei (Molecular Design), pp. 163-198.

(Production Methods)

The compound of the invention and a pharmaceutically acceptable salt thereof can be produced applying various conventionally known synthesis methods, making use of the characteristics based on its basic nucleus and kinds of substituent groups. For example, oxidation, reduction, amination, alkylation, amidation, sulfonamidation, esterification, urea formation and the like reactions can be carried out by referring to the conditions described in references such as “Jikken Kagaku Koza (Experimental Chemistry Series)” 4th edition, edited by The Chemical Society of Japan (1991) (published by Maruzen). In that case, depending on the kinds of functional groups, it is sometimes effective in view of production techniques to replace said functional groups by appropriate protecting groups (groups which can be easily converted into said functional groups) at the stage of the material or an intermediate. Examples of such functional groups include amino group, OH (hydroxyl group), COOH (carboxy) and the like, and examples of their protecting groups include the protecting groups described in “Protective Groups in Organic Synthesis (3rd edition)” edited by Greene and Wuts, which may be optionally selected in response to the reaction conditions. In such a method, the compound of interest can be obtained by eliminating the protecting group as occasion demands after carrying out the reaction by introducing said protecting group.

Materials of the compounds of the invention and production methods of the compounds of the invention are described in detail in the following. Though the compounds of the invention can be produced by conventionally known methods, such as the methods described in Bull. Soc. Chim. Fr., 6, 2112 (1973) and the like, or modified methods thereof, typical production methods are shown in the following.

(In the formulae, L¹, L² and L³ indicate leaving groups.)

As the leaving group, (i) a halogen, (ii) methylsulfanyl, (iii) methylsulfinyl, (iv) a C₁₋₆ alkanesulfonyloxy group which may be substituted with 1 to 3 halogen (e.g., methanesulfonyloxy, trifluoromethanesulfonyloxy or the like), or (v) a C₆₋₁₀ allenesulfonyloxy group which may be substituted with 1 to 4 C₁₋₆ alkyl or halogen (e.g., p-toluenesulfonyloxy, p-bromobenzenesulfonyloxy or the like) can be exemplified.

Process A

The material compound (IV) or (VII) of the compound of the invention can be synthesized by conventionally known methods described in Agric. Biol. Chem., 51, 9, 2563 (1989) and J. Am. Chem. Soc., 116, 4326 (1994) or modified methods thereof.

Process B

The material compound (V), (VI) or (VIII) of the compound of the invention can be synthesized by conventionally known methods described in J. Am. Chem. Soc., 116, 2382 (1994), U.S. Pat. No. 2,476,548, J. Chem. Soc., 561 (1948) and Yuki Gosei Kagaku Kyokai-shi (Journal of the Society of Synthetic Organic chemistry), vol. 18, p. 332 (1960) or modified methods thereof.

Process C

This Process is a method in which the compound (1-a) or (1-b) of the invention is obtained by allowing a compound (IV), (V), (VI) or (VIII) to react with an amine compound (IX) or an aniline compound (X) or (XI). The reaction is carried out under cooling to heating reflux using the compound (IV), (V), (VI) or (VIII) and the compound (IX), (X) or (XI) at an equivalent molar ratio, or one of them in an excess amount, without a solvent or in a solvent inert to the reaction such as benzene, toluene, xylene or the like aromatic hydrocarbon, diethyl ether, tetrahydrofuran (THF), dioxane or the like ether, dichloromethane, 1,2-dichloroethane, chloroform or the like halogenated hydrocarbon, N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMA), N-methylpyrrolidone, ethyl acetate or acetonitrile. The reaction temperature can be optionally set in response to the compounds. Depending on the compounds, it is desirable in some cases to carry out the reaction in the presence of an organic base (preferably diisopropylethylamine, N-methylmorpholine, pyridine or 4-(N,N-dimethylamino)pyridine) or a metal salt base (preferably sodium hydride, potassium carbonate, sodium carbonate, sodium bicarbonate, sodium hydroxide or potassium hydroxide). In addition, depending on the compounds, it is advantageous in some cases to carry out the reaction in the absence of a base, for effecting smooth reaction.

The compound (I) of the invention can be isolated and purified by conventionally known techniques such as solvent extraction, liquid conversion, solvent partition, crystallization, recrystallization, chromatography and the like. In addition, material compound of the compound (III), (IV), (V), (VI), (VII) or (VIII) or a pharmaceutically acceptable salt thereof can be isolated and purified by the same conventionally known techniques as described in the above, but it may be directly used as the material of the subsequent step as a reaction mixture without isolation.

In this connection, the aforementioned Processes are not limited to the substituent groups in the formulae and can be broadly applied to cases in which the compounds of the invention have similar substituent groups.

The compound of the invention produced in such a manner is isolated and purified in its free form or as a pharmaceutically acceptable salt thereof.

The isolation and purification are carried out by employing usual chemical operations such as extraction, concentration, evaporation, crystallization, filtration, recrystallization, various types of chromatography and the like.

Various isomers can be separated by selecting an appropriate material compound or making use of the difference in physical property between isomers. For example, optical isomers can be made into a stereochemically pure isomer by selecting an appropriate material or by subjecting to optical resolution of racemic compound (e.g., a method in which optical resolution is carried out after converting into diastereomer salts with a general optically active base).

INDUSTRIAL APPLICABILITY

The invention relates to an anti-dementia agent which uses a BEC 1 potassium channel inhibitor as the active ingredient.

When a transgenic mouse in which the BEC 1 potassium channel is frequently expressed in the hippocampus and cerebral cortex was prepared and its behavior was analyzed, it was revealed that learning performance of said mouse was reduced in a Morris water maze learning test, a passive avoidance task and a fear conditioning, which are described later. In addition, immunohistochemical detection of the BEC 1 potassium channel using the brain of Alzheimer patients suggested that its expression is increased in nerve cells of the hippocampus and cerebral cortex. The above results suggest a possibility that increase in the expression of the BEC 1 potassium channel in the hippocampus and cerebral cortex of the Alzheimer patient is inhibiting a memory and learning-related neural transmission by reducing excitability of nerve cells.

As a result of further conducting intensive studies, it was confirmed that a BEC 1 potassium channel inhibitor, or a compound shown in Invention Example 744 as a typical compound, has an action to improve an amnesia induced by electroconvulsive shock (ECS) in a mouse passive avoidance task.

Based on the above, it was verified that the BEC 1 potassium channel inhibitor has an action to improve learning disorder and is useful as a preventive or therapeutic agent for a disease in which the BEC 1 potassium channel is considered to be concerned, preferably dementia.

The pharmaceutical composition which contains one or two or more of the BEC 1 potassium channel inhibitors or pharmaceutically acceptable salts thereof as the active ingredient is prepared using generally used pharmaceutical carriers, fillers and other additives.

The pharmaceutical carriers and fillers may be either in solid or liquid forms, and their examples include lactose, magnesium stearate, starch, talc, gelatin, agar, pectin, gum arabic, olive oil, sesame oil, cacao butter, ethylene glycol and the like and other generally used substances.

The administration may be effected in the form of either oral administration by tablets, pills, capsules, granules, powders, solutions or the like or parenteral administration by injections for intravenous injection, intramuscular injection or the like, suppositories, percutaneous preparations and the like.

The dose is optionally decided in response to each case by taking into consideration symptoms and age, sex and the like of each patient to be treated, but is usually within the range of from 1 to 1,000 mg, preferably from 50 to 200 mg, per adult per day by oral administration, or dividing the daily dose into several doses per day, or from 1 to 500 mg by parenteral administration, per day per adult, by dividing the daily dose into 1 to several doses per day, or within the range of from 1 hour to 24 hours per day by intravenous continued administration. Since the dose varies under various conditions as described in the foregoing, a smaller dose than the aforementioned range may be sufficient enough in some cases.

The solid composition for use in the oral administration according to the present invention is used in the form of tablets, powders, granules and the like. In such a solid composition, one or more active substances are mixed with at least one inert diluent such as lactose, mannitol, glucose, hydroxypropylcellulose, microcrystalline cellulose, starch, polyvinyl pyrrolidone or aluminum magnesium silicate. In the usual way, the composition may contain other additives than the inert diluent, such as magnesium stearate or the like lubricant, calcium cellulose glycolate or the like disintegrating agent, lactose or the like stabilizing agent and glutamic acid, aspartic acid or the like solubilization assisting agent.

If necessary, tablets or pills may be coated with a sugar coat or a film of a gastric or enteric substance such as sucrose, gelatin, hydroxypropylcellulose, hydroxypropylmethylcellulose phthalate or the like.

The liquid composition for oral administration includes pharmaceutically acceptable emulsions, solutions, suspensions, syrups, elixirs and the like and contains a generally used inert diluent such as purified water or ethyl alcohol. In addition to the inert diluent, this composition may also contain a moistening agent, a suspending agent and the like auxiliary agents, as well as sweeteners, flavors, aromatics and antiseptics.

The injections for parenteral administration includes aseptic aqueous or non-aqueous solutions, suspensions and emulsions. Examples of the diluent for use in the aqueous solutions and suspensions include distilled water for injection and physiological saline. Examples of the diluent for use in the non-aqueous solutions and suspensions include propylene glycol, polyethylene glycol, olive oil or the like plant oil, ethanol or the like alcohol, polysorbate 80 and the like. Such a composition may further contain additive agents such as an antiseptic, a moistening agent, an emulsifying agent, a dispersing agent, a stabilizing agent (e.g., lactose) and a solubilization assisting agent (e.g., glutamic acid or aspartic acid). These compositions are sterilized by filtration through a bacteria retaining filter, blending of a germicide or irradiation. Alternatively, they may be used by firstly making into sterile solid compositions and dissolving them in sterile water or a sterile solvent for injection use prior to their use.

BEST MODE FOR CARRYING OUT THE INVENTION Examples

Next, the invention is described further in detail based on examples, but the invention is not limited to these examples. In this connection, production methods for the starting compounds to be used in the Invention Examples are described as Reference Examples.

Unless otherwise noted, the term % as used in the following means percent by weight. Other abbreviations as used herein means as follows.

Symbols in the tables are as follows.

Ex: Invention Example Number

Ref: Reference Example Number

F: fluoro, Cl: chloro, NO₂: nitro, OH: hydroxy, CN: cyano, Me: methyl, Et: ethyl, Ph: phenyl, Py: pyridine, Py-2-ylCH₂NH: pyridin-2-ylmethylamino, Py-3-ylCH₂NH: pyridin-3-ylmethylamino, Py-4-ylCH₂NH: pyridin-4-ylmethylamino, CF₃: trifluoromethyl, iPr: isopropyl, Pen: pentyl, cPr: cyclopropyl, cHex: cyclohexyl, Bzl: benzyl, Bz: benzoyl, diMePhNH: dimethylphenylamino, diMeOPhNH: dimethoxyphenylamino, diClPhNH: dichlorophenylamino, diCF₃PhNH: ditrifluoromethylphenylamino, Ac: acetyl, AcOEt: ethyl acetate, free: free form,

NMR: nuclear magnetic resonance spectrum (measured with tetramesylsilane (TMS) internal standard (indicated by ppm))

The ¹H-NMR spectrum is expressed by chemical shift value when TMS is used as the internal standard, and the signals are indicated by the following abbreviations. s: singlet, d: doublet, t: triplet, q: quartet, br: broad, m: multiplet, m.p.: melting point [° C.] (Melting point was measured using a melting point measuring apparatus Yanako MP-S3 manufactured by Yanagimoto and shown by uncorrected value.)

MS: FAB-MS, MASS: ESI-MS, HPLC rt: HPLC retention time

Measuring apparatus: HPLC: 2790 separation module manufactured by WATERS; MS: ZMD manufactured by Micromass

PDA detector: A 996 photodiode array detector manufactured by WATERS

Measuring conditions: Column, WAKOSIL-2 5C18AR, 2.0 mm I.D.×30 mm

Column temperature: 35° C.

Mobile phase solution A=5 mM trifluoroacetic acid aqueous solution, solution B=methanol

Detection wavelength: 254 nm or 210 nm

Sample input: 5 μl

Flow rate: 1.2 ml/min

In this connection, regarding mixing ratio of the mobile phase, the initial stage solvent condition was used as a 10% mobile phase B and increased thereafter to a 100% mobile phase B with linear gradient spending 4 minutes, and the subsequent 0.5 minute was used as a 100% mobile phase B.

Material compounds are shown in Reference Examples.

Reference Example 1

A 2.41 g portion of 2,4-dichloro-6-anilino-1,3,5-triazine was dissolved in 20 ml of acetonitrile, and 2.09 ml of diisopropylethylamine and 1.23 g of p-fluoroaniline were added thereto and stirred overnight at room temperature. The reaction solution was mixed with water and extracted with ethyl acetate, and the organic layer was washed with 1 M hydrochloric acid and saturated brine and then dried using anhydrous magnesium sulfate.

The solvent was evaporated under a reduced pressure, the thus obtained residue was applied to a silica gel column chromatography and eluted with ethyl acetate:n-hexane (1:9), and then the thus obtained crude product was crystallized from benzene, thereby obtaining 2.25 g of 6-chloro-N-(4-fluorophenyl)-N′-phenyl-1,3,5-triazine-2,4-diamine as a white solid.

The compounds of Reference Examples 2 to 5 shown in the following Table 4 were synthesized in the same manner as in Reference Example 1.

Reference Example 6

A 2.59 g portion of 4,6-dichloro-N-(4-fluorophenyl)-1,3,5-triazine was dissolved in 20 ml of acetonitrile, and 2.09 ml of diisopropylethylamine and 1.18 g of p-toluidine were added thereto and stirred overnight at room temperature. The reaction solution was mixed with water and extracted with ethyl acetate, and the organic layer was washed with 1 M hydrochloric acid and saturated brine and then dried using anhydrous magnesium sulfate. The solvent was evaporated under a reduced pressure, the thus obtained residue was applied to a silica gel column chromatography and eluted with ethyl acetate:n-hexane (1:9), and then the thus obtained crude product was crystallized from benzene, thereby obtaining 2.74 g of 6-chloro-N-(4-fluorophenyl)-N′-(4-methylphenyl)-1,3,5-triazine-2,4-diamine as a white solid.

The compounds of Reference Examples 7 to 12 shown in the following Table 4 were synthesized in the same manner as in Reference Example 6.

Invention Example 1

A 200 mg portion of 6-chloro-N,N′-diphenyl-1,3,5-triazine-2,4-diamine was dissolved in 10.0 ml of acetonitrile, and 145 mg of 4-(aminomethyl)pyridine and 0.585 ml of diisopropylethylamine were added thereto and stirred overnight at 80° C. The reaction solution was cooled down to room temperature, and then mixed with water and extracted with chloroform. The organic layer was washed with 5% citric acid and saturated brine and then dried using anhydrous magnesium sulfate. The solvent was evaporated under a reduced pressure, the thus obtained residue was applied to a silica gel column chromatography and eluted with ethyl acetate:n-hexane (2:1), and then the thus obtained crude product was crystallized from ethyl acetate/n-hexane, thereby obtaining 107 mg of N,N′-diphenyl-N″-(4-pyridylmethyl)-1,3,5-triazine-2,4,6-triamine as light red crystals.

The compounds of Invention Examples 2 to 38 and compounds of Invention Examples 740 to 815 shown in the following Tables 5 to 7 and the following Tables 28 to 35 were synthesized in the same manner as in Invention Example 1.

Invention Example 39

A 207 mg portion of (4,6-dichloro-1,3,5-triazin-2-yl)isopropylamine was dissolved in 10.0 ml of acetonitrile, and 369 mg of 4-methoxyaniline was added thereto and stirred at 80° C. for 3 days. The reaction solution was cooled down to room temperature, and then mixed with water and extracted with ethyl acetate. The organic layer was washed with 1 M hydrochloric acid aqueous solution and saturated brine and then dried using anhydrous magnesium sulfate. The solvent was evaporated under a reduced pressure, and the thus obtained residue was applied to a silica gel column chromatography and eluted with ethyl acetate:n-hexane (2:1) to obtain a clued product. This crude product was dissolved in ethyl acetate and mixed with 4 M hydrochloric acid ethyl acetate solution, the solvent was evaporated under a reduced pressure, and the thus obtained residue was crystallized from ethyl acetate, thereby obtaining 332 mg of N-isopropyl-N′,N″-bis(4-methoxyphenyl)-1,3,5-triazine-1,3,5-triamine hydrochloride as colorless crystals.

The compounds of Invention Examples 40 to 44 shown in the following Table 7 were synthesized in the same manner as in Invention Example 39.

Invention Example 45

A 316 mg portion of the 6-chloro-N-(4-fluorophenyl)-N′-phenyl-1,3,5-triazine-2,4-diamine was dissolved in 10.0 ml of acetonitrile, and 0.523 ml of diisopropylethylamine and 0.170 ml of isopropylamine were added thereto and stirred overnight at 80° C. The reaction solution was cooled down to room temperature, and then mixed with water and extracted with ethyl acetate. The organic layer was washed with 5% citric acid aqueous solution and saturated brine and then dried using anhydrous magnesium sulfate. The solvent was evaporated under a reduced pressure, and the thus obtained residue was applied to a silica gel column chromatography and eluted with ethyl acetate:n-hexane (2:1) to obtain a crude product. This crude product was dissolved in ethyl acetate and mixed with 4 M hydrochloric acid ethyl acetate solution, the solvent was evaporated under a reduced pressure, and the thus obtained residue was crystallized from ethyl acetate, thereby obtaining 327 mg of N-(4-fluorophenyl)-N′-isopropyl-N″-phenyl-1,3,5-triazine-2,4,6-triamine hydrochloride as colorless crystals.

The compounds of Invention Examples 46 to 50 shown in the following Table 8 were synthesized in the same manner as in Invention Example 45.

Invention Example 51 A Synthesis Example by Combinatorial Chemistry

A 7.5 mg (60 μmol) portion of p-fluorobenzylamine and 52 μl of diisopropylethylamine were added to a mixed solution of 400 μl of acetonitrile and 120 μl of N-methylpyrrolidone containing 8.9 mg (30 μmol) of 6-chloro-N,N′-diphenyl-1,3,5-triazine-2,4-diamine and stirred at 80° C. for 3 hours. The reaction solution was filtered and then injected into a fractional LC-MS apparatus to collect a fraction containing the desired molecular weight. By evaporating the solvent, 6.1 mg (yield 45%) of N,N′-diphenyl-N″-(4-fluorobenzyl)-1,3,5-triazine-2,4,6-triamine was obtained. A retention time of 2.77 minutes and a purity of 93% were determined by an analytical LC-MS.

The compounds of Invention Examples 52 to 418 shown in the following Tables 9 to 18 were synthesized in the same manner as in Invention Example 51.

Invention Example 419

A 6.7 mg (60 μmol) portion of 2-fluoroaniline was added to a mixed solution of 400 μl of acetonitrile and 120 μl of N-methylpyrrolidone containing 8.9 mg (30 μmol) of 6-chloro-N,N′-diphenyl-1,3,5-triazine-2,4-diamine and stirred at 80° C. for 3 hours. The reaction solution was filtered and then injected into a fractional LC-MS apparatus to collect a fraction containing the desired molecular weight.

By evaporating the solvent, 6.0 mg (yield 54%) of N,N′-diphenyl-N″-(2-fluorophenyl)-1,3,5-triazine-2,4,6-triamine was obtained. A retention time of 3.01 minutes and a purity of 94% were determined by an analytical LC-MS.

The compounds of Invention Examples 420 to 583 shown in the following Tables 19 to 22 were synthesized in the same manner as in Invention Example 419.

Invention Example 584

A 10 mg portion of 2,6-dichloro-N-isopropyl-1,3,5-triazine-4-amine was dissolved in 600 μl of N-methyl-2-pyrrolidone, and 400 μl of 0.5 mM 2-fluoroaniline N,N-dimethylformamide solution and 26 μl of diisopropylethylamine were added thereto and stirred at 120° C. for 3 days. The reaction solution was mixed with 50 mg (4.27 mmol/g) of PS-trisamine manufactured by Algonote and further stirred at 120° C. for 7 hours. After cooling down to 50° C., the reaction solution was mixed with 50 mg (1.53 mmol/g) of PS-benzaldehyde manufactured by Algonote and further stirred at 50° C. for 16 hours. The reaction solution was cooled down to room temperature and then mixed with saturated sodium bicarbonate aqueous solution and chloroform and stirred. After filtration of the solution, the organic layer was dried using anhydrous sodium sulfate, and then the solvent was evaporated under a reduced pressure to obtain 7 mg of N,N′-di-(2-fluorophenyl)-N″-isopropyl-1,3,5-triazine-2,4,6-triamine as a brown resinous substance.

The compounds of Invention Examples 585 to 636 shown in the following Tables 23 and 24 were synthesized in the same manner as in Invention Example 584.

Invention Example 637

A 14 mg portion of 6-chloro-N-isopropyl-N′-phenyl-1,3,5-triazine-2,4-diamine was dissolved in 800 μl of N-methyl-2-pyrrolidone, and 200 μl of 0.5 mM 2-fluoroaniline N,N-dimethylformamide solution and 50 μl of 4 M hydrochloric acid/dioxane were added thereto and stirred at 80° C. for 7 hours. After cooling down the reaction solution to 60° C., 50 mg (4.27 mmol/g) of PS-trisamine and 50 mg (1.53 mmol/g) of PS-benzaldehyde both manufactured by Algonote were added to the reaction solution and further stirred at 60° C. for 16 hours. The reaction solution was cooled down to room temperature and then mixed with saturated sodium bicarbonate aqueous solution and chloroform and stirred. After filtration of the solution, the organic layer was dried using anhydrous sodium sulfate, and then the solvent was evaporated under a reduced pressure to obtain 13 mg of N-(2-fluorophenyl)-N′-isopropyl-N″-phenyl-1,3,5-triazine-2,4,6-triamine as a brown resinous substance.

The compounds of Invention Examples 638 to 739 shown in the following Tables 24 to 27 were synthesized in the same manner as in Invention Example 637.

Invention Example 816

A 565 mg portion of the N-(4-fluorophenyl)-N′-[(6-methoxypyridin-3-yl)methyl]-N″-phenyl-1,3,5-triazine-2,4,6-triamine hydrochloride synthesized in Invention Example 753 was mixed with 5 ml of 25% hydrobromic acid acetic acid solution and 1 ml of 48% hydrobromic acid aqueous solution and stirred at 80° C. for 6 hours. After evaporation of the reaction solution under a reduced pressure, the residue was mixed with ethyl acetate and sodium bicarbonate aqueous solution in that order and extracted with ethyl acetate. The organic layer was washed with saturated brine and dried using anhydrous magnesium sulfate. The solvent was evaporated under a reduced pressure, and the thus obtained residue was applied to a silica gel column chromatography and eluted with chloroform:methanol (99:1) to obtain a crude product. This crude product was dissolved in ethyl acetate and mixed with 4 M hydrochloric acid ethyl acetate solution, and the thus formed crystals were collected by filtration and dried to obtain 195 mg of 5-[({4-anilino-6-[(4-fluorophenyl)amino]-1,3,5-triazin-2-yl}amino)methyl]pyridine-2(1H)-one hydrochloride as colorless crystals.

The compounds of Invention Examples 817 and 818 shown in the following Table 35 were synthesized in the same manner as in Invention Example 816.

Invention Example 819

A 250 mg portion of the tert-butyl {6-[({4-anilino-6-[(4-fluorophenyl)amino]-1,3,5-triazin-2-yl}-)amino]methyl}pyridin-2-yl}carbamate hydrochloride synthesized in Invention Example 758 was dissolved in 10.0 ml of ethyl acetate, and 10.0 ml of 4 M hydrochloric acid ethyl acetate solution was added thereto and stirred at room temperature for 4 hours. The thus formed pale yellow crystals were collected by filtration and dried to obtain 190 mg of N-[(6-aminopyridin-2-yl)methyl]-N′-(4-fluorophenyl)-N″-phenyl-1,3,5-triazine-2,4,6-triamine hydrochloride as pale yellow crystals.

Invention Example 820

A 360 mg portion of the N-(4-fluorophenyl)-N′-{[1-(4-methoxybenzyl)-1H-1,2,4-triazol-5-yl]methyl}-N″-phenyl-1,3,5-triazine-2,4,6-triamine hydrochloride synthesized in Invention Example 767 was dissolved in 5 ml of trifluoroacetic acid and stirred at 70° C. overnight. After evaporation of the reaction solution under a reduced pressure, the residue was mixed with ethyl acetate and sodium bicarbonate aqueous solution in that order and extracted with ethyl acetate. The organic layer was washed with saturated brine and dried using anhydrous magnesium sulfate. The solvent was evaporated under a reduced pressure, and the thus obtained residue was applied to a silica gel column chromatography and eluted with chloroform:methanol (92.8) to obtain a crude product. This crude product was dissolved in ethyl acetate and mixed with 4 M hydrochloric acid ethyl acetate solution, and the thus formed crystals were collected by filtration and dried to obtain 268 mg of N-(4-fluorophenyl)-N′-phenyl-N″-(1H-1,2,4-triazol-3-yl)-1,3,5-triazine-2,4,6-triamine hydrochloride as colorless crystals.

Invention Example 821

A 678 mg portion of [(1-trityl-1H-imidazol-4-yl)methyl]amine was dissolved in 10.0 ml of acetonitrile, and 0.52 ml of diisopropylethylamine and 316 mg of the 6-chloro-N-(4-fluorophenyl)-N′-phenyl-1,3,5-triazine-2,4-diamine synthesized in Reference Example 1 were added thereto and stirred at 80° C. for 3 days. After cooling down to room temperature, the reaction solution was mixed with water and extracted with ethyl acetate. The organic layer was washed with citric acid aqueous solution and saturated brine and dried using anhydrous magnesium sulfate. The solvent was evaporated under a reduced pressure, and the thus obtained residue was applied to a silica gel column chromatography and eluted with chloroform:methanol (99:1) to obtain a crude product. This crude product was dissolved in 9 ml of acetic acid and 1 ml of water and stirred at 70° C. for 2 hours. After evaporation of the reaction solution under a reduced pressure, the residue was mixed with ethyl acetate and sodium bicarbonate aqueous solution in that order and extracted with ethyl acetate. The organic layer was washed with saturated brine and dried using anhydrous magnesium sulfate. The solvent was evaporated under a reduced pressure, and the thus obtained residue was applied to a silica gel column chromatography and eluted with chloroform:methanol (90:10) to obtain a crude product. This crued product was dissolved in ethyl acetate and mixed with 4 M hydrochloric acid ethyl acetate solution, and the thus formed crystals were collected by filtration and dried to obtain 306 mg of N-(4-fluorophenyl)-N′-(1H-imidazol-4-ylmethyl)-N″-phenyl-1,3,5-triazine-2,4,6-triamine hydrochloride as colorless crystals.

In the following, structures and physical property values of the compounds of Reference Examples and Invention Examples are shown in Tables 4 to 35.

In addition, the compounds shown in the following Tables 36 to 39 can also be synthesized in the same manner as in the aforementioned Invention Examples. The sign “No” in the tables indicates compound number.

Invention Example 822 Test Method

Method for measuring BEC 1 inhibitory activity of compounds using released amount of ⁸⁶Rb ions as the index

The channel activity of BEC 1 was measured in accordance with the method described in WO 99/37677, using amount of a radioisotope ⁸⁶Rb ion released from a BEC 1-expressing cell as the index. That is, when an ⁸⁶Rb ion-incorporated BEC 1-expressing cell was stimulated with 100 mM KCl, the radioactivity released from the cell was used as the channel activity of BEC 1. The ⁸⁶Rb ions were incorporated into a BEC 1-stably expressing cell by culturing the cell (3 hours, 37° C.) in the presence of ⁸⁶RbCl (0.5 μCi/ml), and the un-incorporated ⁸⁶Rb ions were removed by washing three times with HEPES-buffered saline (pH 7.4, 2.5 mM KCl). The cells were incubated with HEPES-buffered saline containing a compound to be tested at room temperature for 15 minutes and then further incubated with 100 mM KCl-containing HEPES-buffered saline (pH 7.4) containing the compound to be tested at room temperature for 5 minutes. The extracellular medium was recovered, and then the remaining cells were lysed with 0.1 N NaOH and recovered.

The Cerenkov radioactivity of the extracellular medium and cell lysate was respectively measured, and their total was used as the total radioactivity. The released amount of ⁸⁶Rb ions was expressed by the percentage of extracellular medium radioactivity based on the total radioactivity. The value obtained in the presence of the compound was used as a test value, and the value obtained in the absence of the compound as a control value and the value obtained when not stimulated with 100 mM KCl as a blank value. Inhibitory action of each compound was expressed by % inhibition, namely (control value−test value)×100/(control value−blank value), or by an IC₅₀ value calculated from the % inhibition. As the test results of typical compounds are shown in the following Tables 2 and 3, it was confirmed that said compounds have the BEC 1 potassium channel inhibitory action.

In this connection, as the BEC 1-expressing cell, a BEC 1-stably expressing cell prepared in accordance with the method described in WO 99/37677 using a dihydrofolate reductase (dhfr)-deficient strain of a Chinese hamster ovary cell was used.

TABLE 2 Test results BEC1 Ex IC₅₀(μM) 1 0.084 4 0.079 7 0.39 8 0.29 9 0.052 11 0.43 12 0.29 13 0.18 14 0.39 16 0.36 17 0.29 18 1.1 19 1.3 20 0.32 21 0.59 22 0.19 23 0.24 24 0.48 32 0.24 33 0.97 35 0.24 25 0.11 28 0.39 29 0.35 30 0.073 31 0.49 36 0.48 37 0.26 38 0.18 39 0.66 40 0.63 41 0.40 45 0.22 46 0.49 47 0.72 48 0.29 49 0.14 50 0.49 740 4.9 741 0.52 742 1.4 743 0.10 744 0.085 747 3.6 764 0.047 771 0.25 773 1.5 774 0.55 775 0.11 776 0.14 777 0.21 778 0.45 779 0.70 780 0.34 789 9.5 790 4.7 791 2.2 794 3.1 795 0.24 796 0.17 797 0.65 801 0.25 808 0.42 819 1.4

TABLE 3 Inhibition ratio when concentration of test compound is 3 μM Ex % 52 31 53 59 54 64 62 44 64 19 66 34 76 49 83 23 95 10 96 23 99 36 123 44 130 22 132 21 134 51 167 29 169 33 176 34 182 45 183 33 185 35 187 31 200 50 213 59 215 29 227 33 247 10 428 17 432 40 449 12 495 37 500 31 504 22 531 15 602 11 609 10 623 11 671 25 673 27 723 40 725 18

Invention Example 823

Evaluation of BEC 1 current inhibitory activity by a compound using an electrophysiological technique

BEC 1-expressing cells were voltage-clamped and whole-cell current was recorded by the whole-cell voltage-clamp method. A solution containing 140 mM NaCl, 5.4 mM KCl, 2 mM CaCl₂, 0.8 mM MgCl₂, 15 mM glucose and 10 mM HEPES (pH=7.4 by adding NaOH) was used as the extracellular solution, and a solution containing 125 mM KCl, 1 mM CaCl₂, 2 mM MgCl₂, 11 mM EGTA and 10 mM HEPES (pH=7.2 by adding KOH) was used as the intracellular solution (patch electrode solution).

A continuous outward current is induced by depolarizing the membrane potential from −90 mV to 0 mV. By comparing amplitude of this outward current in the absence of an agent (control value) with the current amplitude at the time of the administration of a compound to be tested (test value), % inhibition [(test value/control value)×100] was calculated.

Test Results

As a result, in the case of the compound of Invention Example 13, it showed 500- or more of inhibition at a concentration of 1 μM.

Invention Example 824 Preparation of Transgenic Mouse <Construction of Transgene for BEC 1-Overexpressing Transgenic Mouse Preparation>

The transgene for production of a transgenic mouse overexpressing BEC1 having the amino acid sequence described in SEQ ID NO:2 comprises a gene in which a BEC 1 cDNA (SEQ ID NO:1) with a 5′ intron and poly(A) addition signal is linked to a downstream of the promoter region of α-calcium-calmodulin-dependent kinase II gene. The promoter region of α-calcium-calmodulin-dependent kinase II was obtained as two fragments having a mutually overlapping region, by PCR using a C57BL/6 mouse genomic DNA as the template. The C57BL/6 mouse genomic DNA was purified from a blood sample of the same mouse using a genomic DNA extraction kit (QIAamp DNA Blood Midi Kit, mfd. by QIAGEN). Primers were designed based on the sequence registered in a gene data base GenBank (Accession No. AJ222796). A gene fragment of 4.6 kb was obtained using an oligonucleotide comprising the nucleotide sequence represented by SEQ ID NO:3 as the forward primer and using an oligonucleotide comprising the nucleotide sequence represented by SEQ ID NO:4 as the reverse primer. An AatII recognition sequence is added to the 5′ terminal side of the aforementioned forward primer. In addition, a gene fragment of 3.7 kb was obtained using an oligonucleotide comprising the nucleotide sequence represented by SEQ ID NO:5 as the forward primer and using an oligonucleotide comprising the nucleotide sequence represented by SEQ ID NO:6 as the reverse primer. A SalI recognition sequence is added to the 5′ terminal side of the aforementioned reverse primer. Each PCR was carried out using a DNA polymerase (Pfu Turbo, mfd. by Stratagene) by employing a thermal denaturation at 99° C. (1 minute) and subsequent repetition of 45 cycles each comprising 99° C. (15 seconds), 58° C. (15 seconds) and 75° C. (10 minutes), or a thermal denaturation at 95° C. (1 minute) and subsequent repetition of 40 cycles each comprising 95° C. (15 seconds), 62° C. (15 seconds) and 75° C. (8 minutes), and the thus obtained gene fragment was cloned into a cloning vector (pCR-XL-TOPO plasmid, mfd. by Invitrogen). An endogenous XmaI recognizing sequence is present in the overlapping region of the 4.6 kb fragment and 3.7 kb fragment. The 4.6 kb fragment was digested with restriction enzymes AatII and XmaI, and the 3.7 kb fragment was digested with restriction enzymes XmaI and SalI. The thus obtained respective fragments were ligated and cloned into a plasmid pUC18 (mfd. by Toyobo) making use of the AatII and SalI recognition sequences. The α-calcium-calmodulin-dependent kinase II promoter region of interest was obtained by the above operation.

On the other hand, the BEC 1 cDNA (SEQ ID NO:1) was obtained as a fragment containing a 5′ intron and poly(A) addition signal by PCR using a potassium channel expression vector pME-E1 (described in WO 99/37677) as the template. An oligonucleotide comprising the nucleotide sequence represented by SEQ ID NO:7 was designed as the forward primer, and an oligonucleotide comprising the nucleotide sequence represented by SEQ ID NO:8 as the reverse primer, respectively from the upstream sequence of 5′ intron and downstream sequence of poly(A) addition signal.

A SalI recognition sequence was added to the aforementioned forward primer, and KpnI and NotI recognizing sequences to the reverse primer. PCR was carried out using a DNA polymerase (Pfu Turbo, mfd. by Stratagene) by employing a thermal denaturation at 96° C. (1 minute) and subsequent repetition of 30 cycles each comprising 96° C. (15 seconds), 60° C. (15 seconds) and 75° C. (8 minutes). The thus obtained 3.7 kb fragment was cloned into a cloning vector (pCR-XL-TOPO plasmid, mfd. by Invitrogen). This fragment was subcloned into a plasmid pUC18 (mfd. by Toyobo) making use of the SpeI recognition sequence and KpnI recognition sequence, and the aforementioned α-calcium-calmodulin-dependent kinase II promoter region was further subcloned into its upstream making use of the AatII recognition sequence and SalI recognition sequence. A plasmid (named pCM-E1 plasmid) having a transgene (12 kb) for use in the preparation of a BEC 1-overexpressing transgenic mouse was finally obtained by the above operation.

<Preparation and Identification of BEC 1 Over-Expression Transgenic Mouse>

The transgene (12 kb) for production of a BEC-overexpressing transgenic mouse was cut out from pCM-E1 using restriction enzymes AatII and NotI and then isolated and purified. The thus obtained gene was micro-injected into 283 fertilized eggs of F1 hybrid mice of C57BL/6 and DBA2 mice, and then the resulting fertilized eggs were transplanted into oviducts of ICR foster mother mice (Hogan, B. et al. (1986), Manipulating the mouse embryo: a laboratory manual, Plainview, N.Y.; Cold Harbor Press). The pregnant mice were allowed to undergo spontaneous delivery, and the thus obtained 81 offspring mice were subjected to the identification of transgenic mice.

In order to identify transgenic mice, PCR was carried out using genomic DNA isolated from the tail of each offspring mouse as the template. The genomic DNA was purified from the tail of each mouse using a genomic DNA extraction kit (MagExtractor -Genome-, mfd. by Toyobo). When an oligonucleotide comprising the nucleotide sequence represented by SEQ ID NO:9 is designed as the forward primer, and an oligonucleotide comprising the nucleotide sequence represented by SEQ ID NO:10 as the reverse primer, from the BEC 1 cDNA (SEQ ID NO:1), and PCR is carried out using them, a 245 bp fragment is amplified from the transgene, and a 338 bp fragment containing 93 bp intron of mouse BEC 1 from the mouse genomic DNA. PCR was carried out on the thus obtained baby mouse genomic DNA preparations using these priers.

PCR was carried out using a DNA polymerase (AmpliTaq, mfd. by Roche) by employing a thermal denaturation at 94° C. (1 minute) and subsequent repetition of 35 cycles each comprising 94° C. (15 seconds), 60° C. (15 seconds) and 72° C. (30 seconds). As a result, it was identified that 16 of the 81 baby mice are transgenic mice.

<Determination of BEC 1 mRNA>

In order to confirm that the introduced gene is actually functioning and BEC 1 mRNA is over-expressing, expression of BEC 1 mRNA in the brain of transgenic mouse was analyzed. In order to obtain F1 mice for brain extraction use, 11 animals among the 16 transgenic mice were crossed with C57BL/6 mice. As a result, transfer of the transgene to F1 mice was confirmed in 5 transgenic mice. The fore-brain and cerebellum were sampled from each of the thus obtained F1 transgenic mice (4-week-old) to isolate respective RNA.

Each RNA was digested with a DNase (mfd. by Promega) for the purpose of preventing contamination of genomic DNA. The number of copies of BEC 1 mRNA in the thus obtained RNA was determined by a real time PCR using PRISM 7700 (mfd. by ABI) and a fluorescence reagent SYBR Green (mfd. by Molecular Probe). A single-stranded cDNA synthesized from each RNA using a reverse transcriptase-polymerase chain reaction kit (Advantage RT-for-PCR Kit, mfd. by Clontech) was used as the template of the real time PCR. An oligonucleotide comprising the nucleotide sequence represented by SEQ ID NO:11 was designed as the forward primer, and an oligonucleotide comprising the nucleotide sequence represented by SEQ ID NO:12 as the reverse primer, from a sequence common to the transgene, human BEC 1, and rat and mouse BEC 1.

As a result of the real time PCR, over-expression of fore-brain-selective BEC 1 mRNA about 10 times larger than that of wild type was found in 3 lines (#6-5, #7-7 and #9-5) among the 5 lines of transgenic mice. By selecting the line #9-5, expressed amounts of BEC 1 mRNA in respective regions of the brain (cerebral cortex, hippocampus, corpus striatum, hypothalamus, thalamus, mid-brain, brain stem, cerebellum) of wild type mouse were compared with those of the transgenic mouse. As a result, it was confirmed that the BEC 1 mRNA over-expression in the transgenic mouse is significant in cerebral cortex, hippocampus and corpus striatum in which the expression was also found in the wild type.

Invention Example 825 Analysis of Learning and Memory of BEC 1-Overexpressing Transgenic Mouse in a Morris Water Maze

In order to analyze action of BEC 1 over-expression upon cognition, learning and memory of #9-5 line transgenic mice and that of wild type mice in a Morris water maze were compared.

Male 10-week-old transgenic mice (12 animals) and wild type mice (15 animals) were used. A circular pool of 100 cm in diameter was filled with water which had been clouded using paints, and a circular platform of 10 cm in diameter was arranged at a position of 5 mm below the water. Room temperature and water temperature at the time of the test was 23° C. Swimming pattern of each mouse put into the pool was recorded and analyzed by a water maze image analyzer (NIH image, mfd. by O'Hara & CO.), and the escape latency to the platform and the time spent in each quadrant of the pool were measured. Maximum trial duration was 70 seconds, and the training was carried out 3 trials per day for 5 days. The escape latency to the platform on the first day of the training was almost the same value in both groups, but the escape latency was prolonged in the transgenic mice than the wild type mice on and after the 3rd day of the start of the training. On the final day of the training, the escape latency to the platform (average value standard deviation) became 6.9±1.0 seconds in the wild type and 18.1±6.4 seconds in the transgenic mice, thus showing a statistically significant difference (p<0.05: two-way layout analysis of variance).

After completion of the training, each mouse received a single 40 seconds test with the platform had been removed, and the time of the mouse spend in the platform-existed quadrant was measured. As a result, the time spend in the platform-existed quadrant of transgenic mice was significantly shorter than that of the wild type (p<0.01: Student's t test).

The above results show that learning and memory on the platform position are reduced in the transgenic mice.

Invention Example 826 Analysis of Learning and Memory of BEC 1-Overexpressing Transgenic Mouse in a Passive Evasion Test

Female #9-5 line transgenic mice (6 animals) and wild type mice (8 animals), 8-week-old, were used. Each mouse was put into the light compartment of a light and dark test apparatus for mice (mfd. by O'Hara & CO.), and a 60 V shock for 2 seconds was applied to the mouse when it entered the dark compartment. The mouse was again put into the light compartment 24 hours thereafter, and the entry latency into the dark compartment at this time was measured.

As a result, the entry latency of the transgenic mice was 167 seconds (median value) which was significantly short compared to the 600 seconds (median value) of the wild type mice (p<0.05: Wilecoxon rank sum test).

It was shown that the ability to learn the dark compartment-related electric shock is reduced in the transgenic mice.

Invention Example 827 Electricity Chorea Shock (ECS)-Induced Learning Disorder Mouse Passive Evasion Reaction Test

The evaluation was carried out in the following manner with reference to a report (Eur. J. Pharmacology, 321; 273-278, 1997).

Animals; Male ddy mice (SLC, five weeks of age at the time of the training) were used. Arranged into 31 or 32 animals per group.

<Test Procedure> Drug Preparation

A compound to be evaluated was suspended in a solution prepared by dissolving methyl cellulose in physiological saline to a concentration of 0.5% (hereinafter, 0.5% methyl cellulose solution). The administration volume was set to 10 ml per 1 kg body weight. As a placebo of the compound to be evaluated, 10 ml of the 0.5% methyl cellulose solution per 1 kg body weight (hereinafter, vehicle) was administered.

Training

(1) Mice were allowed to stand in a laboratory for 1 hour or more on the first day of the test.

(2) Each mouse was put into the light compartment of a passive avoidance task apparatus and allowed to stand for 30 seconds. Thereafter, the Guillotine door was opened. When the mouse received an electric shock (intensity 60 V, delay 1 sec, duration 3 sec) by entering into the dark compartment and then returned into the light compartment, the Guillotine door was closed to let the mouse to stand for 30 seconds in the light compartment.

(3) The mouse was removed and attached with a cornea electrode quickly (within 1 minute), and then an electroconvulsive shock (ECS, 50 Hz, interval 20 ms, duration 10 ms, amplitude 20 mA, gate 1 sec) was applied.

(4) The compound was administered intraperitoneally.

(5) Returned to the home cage.

(6) After completion of the training, allowed to stand in the laboratory for 60 minutes or more and then returned to the rearing room.

Test (24 Hours after the Training)

(1) Animals were allowed to stand in a laboratory for 1 hour or more.

(2) Each mouse was put into the light compartment and allowed to stand for 30 seconds, and then the Guillotine door was opened.

(3) A period of time until the mouse crossed a sensor in the dark compartment after opening the Guillotine door (step-through latency) was recorded. The maximum measuring time was set to 600 seconds.

(4) The step-through latency was employed as the index of the formation of learning. Effect of the compound on ECS-induced amnesia was evaluated by comparison between a step-through latency of (ECS+vehicle administration) group and a that of (ECS+evaluation compound administration) group. Data were analyzed using two-tailed steel test. P<0.05 was considered significant. When the compound described in Invention Example 744 was intraperitoneally administered, its minimum effective dose was 3 mg/kg.

As a result of the above, it was confirmed that the compound described in Invention Example 744 as a typical compound has the BEC 1 potassium channel inhibitory activity and shows the improving effect on electroconvulsive shock (ECS)-induced amnesia in the mouse passive avoidance task.

TABLE 4

(The numbers 2 to 6 in the formula above represent respective bonding positions of R³ and R⁵.) Ref R³ R⁵ DATA: (MS) 1 H 4-F 316 (M⁺ + 1) 2 H 4-CF₃ 366 (M⁺ + 1) 3 H 3-F 316 (M⁺ + 1) 4 H 3,4-diF 334 (M⁺ + 1) 5 H 4-F, 3-Me 330 (M⁺ + 1) 6 4-Me 4-F 330 (M⁺ + 1) 7 4-MeO 4-F 346 (M⁺ + 1) 8 4-Cl 4-F 350 (M⁺ + 1) 9 4-CF₃ 4-F 384 (M⁺ + 1) 10 3-F 4-F 334 (M⁺ + 1) 11 3-Me 4-F 330 (M⁺ + 1) 12 3-MeO 4-F 346 (M⁺ + 1)

TABLE 5

(The numbers 2 to 6 in the formula above represent respective bonding positions of R³ and R⁵.) Ex

R³ R⁵ Salt/Solvate DATA  1 Py-4-ylCH₂NH— H H free m.p.: 159-160 ¹H-NMR: 4.64 (2 H, d, J = 6.4 Hz), 5.50-5.60 (1 H, m), 6.93 (2 H, s), 7.02- 7.10 (2 H, m), 7.24-7.35 (6 H, m), 7.40-7.61 (4 H, m), 8.55-8.58 (2 H, m)/ CDCl₃  2 Py-3-ylCH₂NH— H H 1.9 HCl m.p.: 180-182 0.7 H₂O ¹H-NMR: 4.75 (2 H, d, J = 4.4 Hz), 7.04-7.20 (2 H, m), 7.23-7.42 (4 H, m), 7.43-7.80 (4 H, m), 8.05 (1 H, dd, J = 5.9 Hz, 7.8 Hz), 8.33-8.67 (1 H, m), 8.85 (1 H, d, J = 5.4 Hz), 8.90-9.20 (2 H, m)/DMSO-d₆  3 Py-2-ylCH₂NH— H H free m.p.: 125-127 ¹H-NMR: 4.75 (2 H, d, J = 5.9 Hz), 7.04 (2 H, t, J = 7.5 Hz), 7.14-7.16 (2 H, m), 7.25-7.31 (4 H, m), 7.36 (1 H, d, J = 7.5 Hz), 7.50-7.58 (4 H, m), 7.60- 7.64 (1 H, m), 8.02 (1 H, brs), 8.51 (1 H, d, J = 4.8 Hz)/CDCl₃  4 2-FPy-4-ylCH₂NH— H H HCl m.p.: 202-203 ¹H-NMR: 4.63 (2 H, s), 6.98-7.40 (8 H, m), 7.45-7.60 (2 H, m), 7.61-7.78 (2 H, m), 8.21 (1 H, d, J = 5.4 Hz), 8.75 (1 H, brs), 10.02 (1 H, brs), 10.20 (1 H, brs)/DMSO-d₆  5 2-ClPy-4-ylCH₂NH— H H HCl m.p.: 201-204 0.1 H₂O ¹H-NMR: 4.61 (2 H, s), 7.02-7.19 (2 H, m), 7.26 (2 H, t, J = 7.4 Hz), 7.26-9.80 (8 H, m), 8.38 (1 H, d, J = 5.4 Hz), 8.96 (1 H, brs), 10.21 (1 H, brs), 10.46 (1 H, brs)/DMSO-d₆  6 2-iPrPy-4- H H 2 HCl m.p.: 185-187 ylCH₂NH— 1.34 (6 H, d, J = 6.8 Hz), 3.32-3.50 (1 H, m), 4.73-7.87 (2 H, m), 6.80-7.15 (2 H, m), 7.16-7.28 (2 H, m), 7.30-7.40 (4 H, m), 7.41-7.57 (2 H, m), 7.61- 7.78 (2 H, m), 7.85 (1 H, d, J = 5.9 Hz), 8.93 (1 H, brs), 10.09 (1 H, brs), 10.34 (1 H, brs)/DMSO-d₆  7 BzlNH— H H HCl m.p.: 178-180 0.2 H₂O ¹H-NMR: 4.60 (2 H, brs), 7.05-7.10 (2 H, m), 7.25-7.43 (8 H, m), 7.53-7.75 (4 H, m), 9.15 (1 H, brs), 10.39 (1 H, brs), 10.64 (1 H, brs)/DMSO-d₆  8 4-FPhCH₂NH— H H HCl m.p.: 188-190 ¹H-NMR: 4.57 (2 H, brs), 7.09-7.22 (4 H, m), 7.25-7.50 (6 H, m), 7.52-7.75 (4 H, m), 9.14 (1 H, brs), 10.40 (1 H, brs), 10.64 (1 H, brs)/DMSO-d₆  9

H H 0.4AcOEt m.p.: 81-83¹H-NMR: 4.63 (2 H, d, J = 5.9 Hz), 5.47-5.55 (1 H, m), 6.25 (1 H, dd,J = 1.1 Hz, 3.2 Hz), 6.32 (1 H, dd, J = 1.6 Hz, 3.2 Hz), 6.97 (2 H,brs), 7.05 (2 H,t, J = 7.5 Hz), 7.27-7.34 (4 H, m), 7.36-7.37 (1 H, m), 7.50-7.62 (4 H, m)/CDCl₃ 10

H H HCl m.p.: 165-167¹H-NMR: 2.25 (3 H, s), 4.51 (2 H, s), 6.02 (1 H, d, J = 2.0 Hz),6.15-6.35 (1 H,m), 7.05-7.20 (2 H, m), 7.25-7.45 (4 H, m), 7.55-7.80 (4 H, m), 8.87 (1 H,brs), 10.10-10.70 (2 H, m)/DMSO-d₆ 11

H H HCl m.p.: 188-190¹H-NMR: 4.75 (2 H, brs), 6.97-7.02 (1 H, m), 7.05-7.40 (3 H, m), 7.44 (1 H,d, J = 4.9 Hz), 7.58-7.78 (4 H, m), 9.12 (1 H, brs), 10.40 (1 H, brs), 10.58(1 H, brs)/DMSO-d₆

TABLE 6 (continued from Table 5) 12 Py-4-yl(CH₂)₂NH— H H free m.p.: 228-229 ¹H-NMR: 2.93 (2 H, t, J = 7 Hz), 3.69-3.74 (2 H, m), 5.10 (1 H, brs), 6.79 (1 H, brs), 6.88 (1 H, brs), 7.07 (2 H, t, J = 7.5 Hz), 7.16 (2 H, d, J = 5.9 Hz), 7.30- 7.34 (4 H, m), 7.50-7.65 (4 H, m), 8.53-8.54 (2 H, m)/CDCl₃ 13 iPrNH— H H Known compound 14 PenNH— H H free m.p.: 78-81 ¹H-NMR: 0.91 (3 H, t, J = 7 Hz), 1.31-1.40 (4 H, m), 1.56-1.63 (2 H, m), 3.41 (2 H, q, J = 7 Hz), 5.10-5.18 (1 H, m), 7.02-7.07 (4 H, m), 7.28-7.32 (4 H, m), 7.53-7.65 (4 H, m)/CDCl₃ 15 cPrCH₂NH— H H HCl m.p.: 197-199 ¹H-NMR: 0.26-0.32 (2 H, m), 0.44-0.54 (2 H, m), 1.04-1.16 (1 H, m), 3.22- 3.32 (2 H, m), 7.07-7.21 (2 H, m), 7.28-7.43 (4 H, m), 7.50-7.80 (4 H, m), 8.73 (1 H, brs), 10.10-10.90 (2 H, m)/DMSO-d₆ 16 HCCCH₂NH— H H HCl m.p.: 195-197 ¹H-NMR: 3.25 (1 H, s), 4.16 (2 H, s), 7.05-7.17 (2 H, m), 7.28-7.40 (4 H, m), 7.60-7.80 (4 H, m), 8.65 (1 H, brs), 10.10-10.45 (2 H, m)/DMSO-d₆ 17 MeO(CH₂)₂NH— H H free m.p.: 128-129 ¹H-NMR: 3.39 (3 H, s), 3.59 (2 H, t, J = 4.3), 3.63-3.67 (2 H, m), 6.18 (1 H, brs), 7.01-7.07 (3 H, m), 7.19 (1 H, brs), 7.29-7.33 (4 H, m), 7.51-7.64 (4 H, m)/CDCl₃ 18 MeO(CH₂)₃NH— H H HCl m.p.: 154-155 ¹H-NMR: 1.76-1.87 (2 H, m), 3.25 (3 H, s), 3.37-3.45 (4 H, m), 7.05-7.20 (2 H, m), 7.27-7.42 (4 H, m), 7.50-7.80 (4 H, m), 8.50 (1 H, s), 10.10-10.64 (2 H, m)/DMSO-d₆ 19 MeS(CH₂)₃NH— H H HCl m.p.: 162-163 1.79-1.90 (2 H, m), 2.06 (3 H, s), 2.55 (2 H, t, J = 7.3 Hz), 3.38-3.52 (2 H, m), 7.06-7.20 (2 H, m), 7.26-7.44 (4 H, m), 7.53- 7.82 (4 H, m), 8.66 (1 H, brs), 10.10-10.80 (2 H, m)/DMSO-d₆ 20

H H free m.p.: 149-150¹H-NMR: 1.62-1.71 (1 H, m), 1.86-2.04 (3 H, m), 3.47-3.54 (1 H, m), 3.66-3.72 (1 H, m), 3.74-3.80 (1 H, m), 3.88-3.94 (1 H, m), 4.08-4.14 (1 H, m),6.28 (1 H, brs), 7.03-7.08 (3 H, m), 7.28-7.37 (5 H, m), 7.50-7.63 (4 H, m)/CDCl₃ 21 HO(CH₂)₃NH— H H HCl m.p.: 191-192 ¹H-NMR: 1.69-1.79 (2 H, m), 3.38-3.55 (4 H, m), 7.07-7.20 (2 H, m), 7.26- 7.43 (4 H, m), 7.50-7.85 (4 H, m), 8.60 (1 H, brs), 10.10-10.75 (2 H, m)/ DMSO-d₆ 22 HO(CH₂)₅NH— H H free m.p.: 118-119 ¹H-NMR: 1.42-1.49 (2 H, m), 1.58-1.67 (6 H, m), 3.40-3.46 (2 H, m), 3.65 (2 H, t, J = 6.4), 5.16 (1 H, s), 6.98-7.07 (4 H, m), 7.29-7.33 (4 H, m), 7.50- 7.64 (4 H, m)/CDCl₃ 23 HO(CH₂)₂O(CH₂)₂NH— H H HCl m.p.: 167-169 ¹H-NMR: 3.46-3.62 (8 H, m), 7.09-7.17 (2 H, m), 7.30-7.40 (4 H, m), 7.60- 7.75 (4 H, m), 8.47 (1 H, brs), 10.15-10.70 (2 H, m)/DMSO-d₆ 24

H H HClH₂O m.p.: 138-140¹H-NMR: 4.24-4.30 (1 H, m), 4.33-4.45 (1 H, m), 4.50-5.00 (4 H, m), 7.03-7.10 (2 H, m), 7.25-7.35 (4 H, m), 7.60-7.75 (4 H, m), 8.17 (1 H, brs), 9.70-9.95 (2 H, m)/DMSO-d₆ 25 Py-4-ylCH₂NH— 4-F 4-F 1.8 HCl m.p.: 191-193 H₂O ¹H-NMR: 4.80 (2 H, s), 6.98-7.30 (6 H, m), 7.31-7.95 (6 H, m), 8.03 (2 H, d, J = 5.9 Hz), 8.70-9.00 (3 H, m), 9.75-10.95 (2 H, m)/DMSO-d₆ 26 Py-3-ylCH₂NH— 4-F 4-F 1.8 HCl m.p.: 208-210 0.8 H₂O ¹H-NMR: 4.62-4.84 (2 H, m), 4.05-7.28 (4 H, m), 7.33-7.83 (4 H, m), 8.06 (1 H, dd, J = 5.8 Hz, 7.9 Hz), 8.57 (1 H, brs), 8.85 (1 H, d, J = 5.9 Hz), 8.96 (1 H, brs), 9.77-10.85 (2 H, m)/DMSO-d₆

TABLE 7 (contmued from Table 6) 27 Py-2-ylCH₂NH— 4-F 4-F 2 HCl m.p.: 175-176 ¹H-NMR: 4.88 (2 H, d, J = 4.9 Hz), 7.00-7.29 (4 H, m), 7.30-7.98 (6 H, m), 8.43 (1 H, t, J = 7.8 Hz), 8.62 (1 H, brs), 8.82 (1 H, d, J = 5.4 Hz), 9.70- 10.40 (2 H, m)/DMSO-d₆ 28 BzlNH— 4-F 4-F HCl m.p.: 176-178 0.7 H₂O ¹H-NMR: 4.57 (2 H, brs), 7.08-7.31 (5 H, m), 7.32-7.42 (4 H, m), 7.46- 7.77 (4 H, m), 9.06 (1 H, brs), 10.33 (1 H, brs), 10.59 (1 H, brs)/DMSO- d₆ 29 4-FPhCH₂NH-4-F 4-F 4-F HCl m.p.: 166-167 ¹H-NMR: 4.54 (2 H, brs), 7.08-7.26 (6 H, m), 7.32-7.48 (2 H, m), 7.50- 7.80 (4 H, m), 8.92 (1 H, brs), 9.85-10.75 (2 H, m)/DMSO-d₆ 30

4-F 4-F HCl m.p.: 179-180¹H-NMR: 4.55 (2 H, s), 6.26-6.47 (2 H, m), 7.10-7.24 (4 H, m), 7.51-7.79 (5 H, m), 8.65 (1 H, brs), 9.80-10.55 (2 H, m)/DMSO-d₆ 31

4-F 4-F HCl m.p.: 180-182¹H-NMR: 4.73 (2 H, brs), 6.94-7.02 (1 H, m), 7.05-7.26 (5 H, m), 7.43(1 H, d, J = 4.9 Hz), 7.52-7.78 (4 H, m), 8.97 (1 H, brs), 10.10-10.72 (2 H,m)/DMSO-d₆ 32 iPrNH— 4-F 4-F HCl m.p.: 186-188 ¹H-NMR: 1.21 (6 H, d, J = 6.4 Hz), 3.97-4.33 (1 H, m), 7.10-7.30 (4 H, m), 7.43-7.87 (4 H, m), 8.58 (1 H, brs), 9.98-11.03 (2 H, m)/DMSO-d₆ 33 PenNH— 4-F 4-F HCl m.p.: 170-171 H₂O ¹H-NMR: 0.88 (3 H, t, J = 6.9 Hz), 1.20-1.40 (4 H, m), 1.45- 1.65 (2 H, m), 3.34 (2 H, s), 7.08-7.30 (4 H, m), 7.45- 7.85 (4 H, m), 8.61 (1 H, brs), 9.90-11.00 (2 H, m)/DMSO-d₆ 34 cPrCH₂NH— 4-F 4-F HCl m.p.: 184-186 0.7 H₂O ¹H-NMR: 0.20-0.36 (2 H, m), 0.40-0.57 (2 H, m), 0.98-1.21 (1 H, m), 3.36 (2 H, s), 7.07-7.30 (4 H, m), 7.35-7.85 (4 H, m), 8.79 (1 H, brs), 10.45 (1 H, brs), 10.71 (1 H, brs)/DMSO-d₆ 35 MeO(CH₂)₂NH— 4-F 4-F HCl m.p.: 175-176 ¹H-NMR: 3.29 (3 H, s), 3.48-3.56 (4 H, m), 7.11-7.26 (4 H, m), 7.46- 7.78 (4 H, m), 8.54 (1 H, brs), 10.20-10.80 (2 H, m)/DMSO-d₆ 36

4-F 4-F HCl1.4 H₂O m.p.: 171-174¹H-NMR: 1.51-1.65 (1 H, m), 1.73-2.04 (3 H, m), 3.30-3.52 (2 H, m),3.58-3.80 (1 H, m), 3.82-3.87 (1 H, m), 3.95-4.07 (1 H, m), 7.09-7.28(4 H, m), 7.46-7.81 (4 H, m), 8.60 (1 H, brs), 9.95-11.00 (2 H, m)/DMSO-d₆ 37 HO(CH₂)₅NH— 4-F 4-F HCl m.p.: 162-163 ¹H-NMR: 1.29-1.40 (2 H, m), 1.40-1.50 (2 H, m), 1.51-1.63 (2 H, m), 3.29-3.44 (4 H, m), 7.03-7.27 (4 H, m), 7.52-7.79 (4 H, m), 8.62 (1 H, brs), 10.20-10.76 (2 H, m)/DMSO-d₆ 38 HO(CH₂)₂O(CH₂)₂NH 4-F 4-F HCl m.p.: 151-152 ¹H-NMR: 3.40-3.67 (8 H, m), 7.10-7.28 (4 H, m), 7.36-7.90 (4 H, m), 8.65 (1 H, brs), 9.95-11.05 (2 H, m)/DMSO-d₆ 39 iPrNH— 4-MeO 4- HCl m.p.: 188-190 MeO ¹H-NMR: 1.21 (6 H, d, J = 5.8 Hz), 3.75 (6 H, s), 6.77-7.05 (4 H, m), 7.30- 7.67 (4 H, m), 8.70 (1 H, brs), 9.75-11.15 (2 H, m)/DMSO-d₆ 40 iPrNH— 3-MeO 3- HCl m.p.: 180-182 MeO ¹H-NMR: 1.23 (6 H, d, J = 6.8 Hz), 3.74 (6 H, s), 4.10-4.23 (1 H, m), 6.64- 6.81 (2 H, m), 7.10-7.52 (6 H, m), 8.65 (1 H, brs), 10.00-11.05 (2 H, m)/ DMSO-d₆

TABLE 8 (continued from Table 7) 42 iPrNH— 4-NO₂ 4-NO₂ 0.1 m.p.: 287-288 AcOEt ¹H-NMR: 1.22 (6H, d, J = 6.9 Hz), 4.14-4.26 (1H, m), 7.48 (1H, d, J = 7.8 Hz), 8.06-8.23 (8H, m), 9.88 (1H, s), 10.00 (1H, s)/DMSO-d₆ 43 iPrNH— 4-CF₃ 4-CF₃ AcOEt m.p.: 176-177 ¹H-NMR: 1.20 (6H, d, J = 6.9 Hz), 4.12-4.23 (1H, m), 7.23 (1H, d, J = 7.9 Hz), 7.55-7.65 (4H, m), 8.05 (4H, d, J = 7.8 Hz), 9.45 (1H, s), 9.59 (1H, s)/ DMSO-d₆ 44 iPrNH— 4-CN 4-CN 0.4 m.p.: 241-242 AcOEt ¹H-NMR: 1.20 (6H, d, J = 6.8 Hz), 4.11-4.24 (1H, m), 7.36 (1H, d, J = 8.3 Hz), 7.66-7.76 (4H, m), 7.98-8.10 (4H, m), 9.62 (1H, s), 9.73 (1H, s)/DMSO-d₆ 45 iPrNH— H 4-F HCl m.p.: 205-206 ¹H-NMR: 1.22 (6H, d, J = 6.4 Hz), 4.02-4.28 (1H, m), 7.07-7.27 (3H, m), 7.29-7.45 (2H, m), 7.46-7.85 (4H, m), 8.75 (1H, brs), 10.10-11.25 (2H, m)/ DMSO-d₆ 46 iPrNH— H 4-Cl HCl m.p.: 201-203 ¹H-NMR: 1.22 (6H, d, J = 6.4 Hz), 4.00-4.30 (1H, m), 7.08-7.23 (1H, m), 7.32-7.47 (4H, m), 7.52-7.85 (4H, m), 8.69 (1H, brs), 10.15-11.15 (2H, m)/ DMSO-d₆ 47 iPrNH— H 4-Me 1.5HCl m.p.: 194-195 ¹H-NMR: 1.22 (6H, d, J = 6.4 Hz), 2.30 (3H, s), 4.00-4.32 (1H, m), 7.06-7.26 (3H, m), 7.27-7.84 (6H, m), 8.82 (1H, brs), 10.55 (1H, brs), 10.94 (1H, brs)/DMSO-d₆ 48 iPrNH— H 4-MeO 1.2HCl0.2H₂O m.p.: 174-177 ¹H-NMR: 1.22 (6H, d, J = 6.3 Hz), 3.76 (3H, s), 4.00-4.25 (1H, m), 6.85-7.05 (2H, m), 7.06-7.22 (1H, m), 7.25-7.80 (6H, m), 8.77 (1H, brs), 9.90-11.20 (2H, m)/DMSO-d₆ 49 iPrNH— H 4-CF₃ HCl m.p.: 198-200 ¹H-NMR: 1.24 (6H, d, J = 6.3 Hz), 4.06-4.26 (1H, m), 7.07-7.22 (1H, m), 7.32-7.45 (2H, m), 7.69 (4H, d, J = 8.3 Hz), 7.86-8.04 (2H, m), 8.63 (1H, brs), 10.17-11.15 (2H, m)/DMSO-d₆ 50 iPrNH— H 3-Me HCl0.1H₂O m.p.: 182-184 MS: 335 (M⁺ + 1) ¹H-NMR: 1.23 (6H, d, J = 6.3 Hz), 2.31 (3H, s), 4.00-4.30 (1H, m), 6.88-7.05 (1H, m), 7.05-7.80 (8H, m), 8.61 (1H, brs), 9.90-11.05 (2H, m)/ DMSO-d₆

Compound of Example 41

DATA

1 HCl

m.p.: 184-186

¹H-NMR: 1.20 (6H, d, J=6.8 Hz), 3.85-4.40 (1H, m), 6.02 (4H, s), 6.77-7.07 (4H, m), 7.10-7.55 (2H, m), 8.55 (1H, brs), 9.85-10.85 (2H, m)/DMSO-d₆

TABLE 9

HPLC Ex R¹ MASS rt(min) 51 4-FPhCH₂— 387 2.77 52 Me 293 2.26 53 Et 307 2.40 54 Pr 321 2.57 55 iPr 321 2.56 56 Bu 335 2.75 57 iBu 349 2.91 58 Pen 349 2.93 59 1-Me-Hex 377 3.18 60 1-Pr-Bu 377 3.12 61 Tetradecyl 475 4.02 62 cPr 319 2.41 63

424 2.13 64 cPen 347 2.76 65

390 2.12 66

393 2.84 67

455 3.16 68

416 2.16 69

430 2.20 70

445 2.15 71

432 2.10 72

363 2.17 73

438 2.38 74

438 2.38 75

527 2.93 76

395 2.63 77

418 1.99 78

432 2.09 79

447 1.99 80

434 1.99 81 cHex 361 2.91 82

404 2.27

TABLE 10 (continued from Table 9) HPLC Ex R¹ MASS rt(min) 83 2-HOcHex 377 2.55 84

430 2.27 85

444 2.35 86

459 2.30 87

446 2.28 88

377 2.35 89

417 3.42 90

403 3.31 91

402 2.25 92

452 2.25 93

434 2.74 94 cHep 375 3.03 95

390 2.37 96

390 2.36 97 cOct 389 3.16 98

350 2.09 99 EtO—CO(Me)CH— 379 2.66 100

389 3.15 101

364 2.01 102

390 2.00 103

438 2.26 104

404 2.08 105

452 2.37 106

419 1.98 107

481 2.48 108

499 2.55 109

482 2.09 110

495 2.34 111

406 2.00 112

337 2.24 113

420 2.09 114

421 3.13 115

392 2.69 116 (HOCH₂)₂CH— 353 2.01

TABLE 11 (continued from Table 10) HPLC Ex R¹ MASS rt(min) 117

381 2.27 118

456 2.63 119

496 2.65 120

511 2.54 121

498 2.60 122

351 2.39 123 H₂C═CHCH₂— 319 2.48 124 HC≡CCH₂— 317 2.39 125

521 2.59 126 2-HOPr 337 2.22 127 HOCH₂(HO)CHCH₂— 353 2.06 128 Me₂NCH₂(Me)₂CCH₂— 392 1.97 129 HOCH₂(Me)₂CCH₂— 365 2.45 130 H₂NCOCH₂— 336 2.01 131 4-NCPhNHCOCH₂— 437 2.50 132 EtO₂CCH₂— 365 2.50 133 tBuO₂CCH₂— 393 2.80 134 cPr-CH₂— 333 2.60 135

390 1.95 136

363 2.43 137

415 3.34 138

486 2.39 139 Et₂N(CH₂)₂— 378 1.91 140 iPr₂N(CH₂)₂— 406 2.06 141

376 1.88 142

424 2.16 143

390 1.88 144

390 1.97 145

392 1.86 146 AcNH(CH₂)₂— 364 2.15 147 Et(3-MePh)N(CH₂)₂— 440 2.65 148 MeO(CH₂)₂— 337 2.32 149 HO(CH₂)₂O(CH₂)₂— 367 2.18 150 EtO₂C(CH₂)₃— 393 2.62 151 Me₂N(CH₂)₃— 364 1.84 152 Et₂N(CH₂)₃— 392 1.91 153

390 1.93 154

404 2.29

TABLE 12 (continued from Table 11) HPLC Ex R¹ MASS rt(min) 155

418 2.02 156

419 1.83 157

406 1.89 158 HO(CH₂)₃— 337 2.18 159 MeO(CH₂)₃— 351 2.43 160 MeS(CH₂)₃— 367 2.65 161 HO(CH₂)₅— 365 2.36 162 iBu 335 2.73 163 2-MecHex 375 3.01 164

389 3.15 165 Me₂N(CH₂)₂— 350 1.85 166 PhSO₂(CH₂)₂— 447 2.53 167 EtO₂C(CH₂)₃— 393 2.65 168 Bzl 369 2.70 169 2-FPhCH₂— 387 2.75 170 2-ClPhCH₂— 403 2.90 171 2-BrPhCH₂— 448 2.95 172 2-CF₃PhCH₂— 437 3.02 173 2-MePhCH₂— 383 2.85 174 2-MeOPhCH₂— 399 2.74 175 2-(2-HOCH₂PhS)PhCH₂— 507 2.92 176 3-FPhCH₂— 387 2.78 177 3-ClPhCH₂— 403 2.94 178 3-IPhCH₂— 495 3.03 179 3-O₂NPhCH₂— 414 2.71 180 3-CF₃PhCH₂— 437 3.03 181 3-MeOPhCH₂— 399 2.71 182 4-ClPhCH₂— 403 2.94 183 4-BrPhCH₂— 448 2.99 184 4-CF₃PhCH₂— 437 3.04 185 4-MePhCH₂— 383 2.86 186 4-tBuPhCH₂— 425 3.21 187 4-MeOPhCH₂— 399 2.67 188 2,3-diMeOPhCH₂— 429 2.67 189 2,4-diMeOPhCH₂— 429 2.73 190 2,6-diFPhCH₂— 405 2.76 191 3,4-diClPhCH₂— 438 3.14 192 2,6-diHOPhCH₂— 401 2.24 193 3,5-diMeOPhCH₂— 429 2.73 194 2,4,6-triMeOPhCH₂— 459 2.83 195

383 2.81 196

383 2.80 197 Ph₂CH— 445 3.14 198

459 3.15 199

399 2.54 200

399 2.54 201

427 2.85 202 4-MeOPh(cPr)CH— 439 2.89

TABLE 13 (continued from Table 12) HPLC Ex R¹ MASS rt(min) 203

438 2.46 204

411 2.66 205

443 3.23 206

409 3.02 207

397 2.86 208

413 2.66 209

359 2.54 210

375 2.66 211

409 2.19 212

370 2.00 213

370 1.89 214

370 1.82 215

385 2.28 216 Ph(CH₂)₂— 383 2.81 217 2-FPh(CH₂)₂— 401 2.82 218 2-MePh(CH₂)₂— 397 2.93 219 2-MeOPh(CH₂)₂ 413 2.84 220 3-FPh(CH₂)₂ 401 2.85 221 3-ClPh(CH₂)₂ 417 3.00 222 3-MePh(CH₂)₂— 397 2.95 223 3-HOPh(CH₂)₂— 399 2.48 224 3-MeOPh(CH₂)₂— 413 2.77 225 4-FPh(CH₂)₂— 401 2.85 226 4-ClPh(CH₂)₂— 417 3.01 227 4-O₂NPh(CH₂)₂— 428 2.76 228 4-MePh(CH₂)₂— 397 2.97 229 4-HOPh(CH₂)₂— 399 2.41 230 4-MeOPh(CH₂)₂— 413 2.76 231 4-PhOPh(CH₂)₂— 475 318 232 4-H₂NSO₂Ph(CH₂)₂— 462 2.25 233 2,4-di-ClPh(CH₂)₂— 452 3.19 234 2,5-di-MeOPh(CH₂)₂— 443 2.79 235 3,4-di-ClPh(CH₂)₂— 452 3.17 236 3-Br-4-MeOPh 492 2.90 237 4-HO-3-MeOPh 429 2.43 238 3,4-di-MeOPh 443 2.59

TABLE 14

HPLC Ex R¹ R² MASS rt(min) 239

H 426 2.60 240

H 441 2.86 241

H 431 3.07 242

H 506 2.34 243

H 399 2.57 244

H 415 2.18 245

H 395 2.94 246

H 386 2.58 247

H 389 2.74 248

H 422 2.68 249

H 384 1.81 250

H 284 1.85 251

H 494 2.95 252 Ph(CH₂)₃— H 397 2.92 253 Ph₂CH(CH₂)₂— H 473 3.16 254

H 387 1.78 255 Ph(CH₂)₄— H 411 3.05 256 3-PhOPhCH₂— H 461 3.13 257

H 505 3.08 258

H 395 2.92 259

H 433 3.05 260

H 454 3.00 261

H 415 2.08 262

H 443 2.57 263

H 439 2.36 264 2-ClPh(CH₂)₂— H 417 2.95 265

H 426 2.18 266

H 452 2.16 267

H 468 2.15 268

H 432 2.33 269

H 423 2.20 270 Me Me 307 2.41 271 Bzl Me 383 3.08 272 NCCH₂— Me 332 2.59 273 EtO₂CCH₂— Me 379 2.72 274 Ph(CH₂)₂— Me 397 3.14

TABLE 15 (continued from Table 14) HPLC Ex R¹ R² MASS rt(min) 275

Me 457 2.84 276 Me Et₂N(CH₂)₂— 392 1.87 277 Me

464 2.28 278 Me

409 2.81 279 cHex Me 375 3.19 280 Me

444 2.38 281 Me

460 2.35 282 Me

416 2.33 283

Me 390 1.84 284 Et Et 335 2.87 285 iPr Et 349 2.92 286 Bzl Et 397 3.21 287 Et₂N(CH₂)₂— Et 406 2.06 288 HO(CH₂)₂— Et 351 2.31 289 cHex Et 389 3.34 290 H₂C═CHCH₂—

444 2.60 291 Bzl iPr 411 3.28 292 MeO(CH₂)— iPr 379 2.84 293 HO(CH₂)₂— HO(CH₂)₂— 367 1.98 294 MeO(CH₂)₂— MeO(CH₂)₂— 395 2.61 295 MeO(CH₂)₂—

451 3.13 296 MeO(CH₂)₂—

462 2.48 297 Bu Bu 391 3.45 298 cHex cHex 443 3.71 299 EtO₂CCH₂— EtO₂CCH₂— 451 2.92 300 Bzl NC(CH₂)₃— 422 3.06 301 Bzl HO(CH₂)₂— 413 2.80 302 Bzl EtO₂CCH₂— 455 3.28 303 Bzl EtO₂C(CH₂)₂— 469 3.28 304 Bzl Bzl 459 3.55 305

cHep 523 3.55 306 Me Pr 335 2.84 307

Me 403 3.17 308

492 2.59 309 secBu secBu 391 3.43 310 Pr Pr 363 3.17 311 Pr Et 349 2.98 312

Me 457 2.84 313

Me 452 0.80 314 Me Me₂N(CH₂)₂— 364 1.40

TABLE 16

Ex

MASS HPLCrt(min) 315

335 2.22 316

402 2.11 317

417 2.08 318

447 2.04 319

404 2.12 320

333 2.63 321

377 2.71 322

391 2.71 323

390 2.23 324

448 2.88 325

349 2.22 326

349 2.23 327

407 2.27 328

381 3.35 329

347 2.90 330

377 2.57 331

391 2.68 332

390 2.29 333

419 2.99 334

363 2.38 335

377 2.46 336

361 3.12 337

390 2.18 338

419 2.95 339

390 1.98 340

363 2.32 341

437 3.50 342

538 2.21 343

379 2.47 344

448 3.28 345

439 2.93 346

473 3.16 347

453 3.01 348

345 2.93 349

421 3.50 350

361 2.46

TABLE 17 (continued from Table 16) Ex

MASS HPLCrt(min) 351

395 3.35 352

439 3.31 353

455 3.02 354

362 2.00 355

390 2.08 356

376 2.36 357

420 2.95 358

442 2.76 359

447 2.25 360

406 2.10 361

436 2.03 362

406 2.02 363

432 2.12 364

462 2.41 365

461 2.02 366

464 2.33 367

446 2.24 368

424 3.27 369

442 3.39 370

458 3.57 371

438 3.58 372

454 3.09 373

458 3.57 374

492 3.57 375

438 3.37 376

454 3.26 377

442 3.29 378

454 3.01 379

463 2.91 380

438 2.37 381

482 2.36 382

514 2.99 383

425 2.23 384

349 2.56

TABLE 18 (continued from Table 17) Ex

MASS HPLCrt(min) 385

377 3.00 386

365 2.97 387

361 3.04 388

376 1.97 389

409 3.15 390

423 3.30 391

409 3.22 392

423 3.26 393

473 2.71 394

391 2.56 395

390 2.13 396

470 2.95 397

470 2.97 398

470 2.95 399

542 2.84 400

392 2.01 401

422 1.98 402

420 2.11 403

476 2.37 404

468 2.42 405

468 2.46 406

472 2.58 407

468 2.40 408

428 2.30 409

439 2.18 410

439 2.05 411

448 2.75 412

376 2.09 413

376 2.04 414

406 2.10 415

406 2.01 416

391 2.55 417

425 3.00 418

377 2.41

TABLE 19

HPLC Ex R¹ MASS rt(min) 419 2-FPh 373 3.01 420 Ph 355 2.86 421 2-ClPh 389 3.23 422 2-BrPh 434 3.25 423 2-MeOPh 385 2.93 424 2-MePh 369 2.84 425 2-EtPh 383 2.98 426 2-PrPh 397 3.15 427 2-iPrPh 397 3.08 428 2-MeSPh 401 3.08 429 2-NCPh 380 2.84 430 2-H₂NCOPh 398 2.83 431 2-HOPh 371 2.64 432 2-HO(CH₂)₂Ph 399 2.59 433 2-EtOPh 399 3.12 434 2-AcPh 397 3.22 435 2-EtO₂CPh 427 3.54 436 2-PhPh 431 3.22 437 2-BzPh 459 3.39 438

460 2.85 439 2-PhOPh 447 3.39 440

440 3.10 441

438 2.84 442

546 3.15 443 3-FPh 373 3.09 444 3-ClPh 389 3.25 445 3-BrPh 434 3.30 446 3-EtO₂CPh 427 3.18 447 3-MeOPh 385 2.91 448 3-MeSPh 401 3.12 449 3-O₂NPh 400 3.12 450 3-AcPh 397 2.89 451 3-NCPh 380 2.93 452 3-CF₃Ph 423 3.34 453 3-HOPh 371 2.52 454 3-H₂NCOPh 398 2.49 455 3-MeO₂CPh 413 3.05 456 3-HOCH₂Ph 385 2.53 457 3-PhOPh 447 3.41 458 3-BzPh 459 3.25 459 3-PhCH₂OPh 461 3.37 460 4-Ph 373 2.94 461 4-ClPh 389 3.24 462 4-BrPh 434 3.31 463 4-MeOPh 385 2.74 464 4-F₃CPh 423 3.38 465 4-AcPh 397 2.92 466 4-MeO₂CPh 413 3.08 467 4-BuO₂CPh 455 3.50 468 4-O₂NPh 400 3.20 469 4-H₂NSO₂Ph 434 2.50 470 4-PrPh 397 3.30 471 4-iPrPh 397 3.27 472 4-tBuPh 411 3.38 473 4-Me₂NPh 398 2.25 474 4-Et₂NPh 426 2.31 475 4-MeSPh 401 3.09 476 4-HepPH 453 3.83 477 4-HOPh 371 2.37 478 4-H₂NCOPh 398 2.51 479 4-NCPh 380 3.01 480 4-AcNHPh 412 2.46

TABLE 20 (continued from Table 19) HPLC Ex R¹ MASS rt(min) 481 4-EtO₂CPh 427 3.22 482 4-EtO₂CCH₂Ph 441 2.97 483 4-NCCH₂Ph 394 2.67 484 4-HexPh 439 3.72 485 4-secBuPh 411 3.42 486 4-PhOPh 447 3.33 487 4-BzPh 459 3.29 488

517 2.58 489

440 2.61 490

438 2.30 491 4-cHexPh 437 3.61 492

502 3.82 493

422 2.75 494 2,3-di-FPh 391 3.15 495 3-HO-2-MePh 385 2.46 496 2,4-di-ClPh 424 3.58 497 4-HO-2-O₂NPh 416 2.83 498

429 2.83 499 3-Cl-5-MePh 403 3.19 500 4-HO-2-MePh 385 2.43 501

493 3.65 502

520 3.20 503 2,5-di-MePh 383 3.00 504 2-Me-5-O₂NPh 414 3.05 505 2-HO-5-tPenPh 441 3.30 506 3,4-di-ClPh 424 3.51 507 3-HO-4-O₂NPh 416 2.95 508 3-F-4-MePh 387 3.21 509

456 2.08 510 4-F-3-O₂NPh 418 3.13 511 3-Cl-4-HOPh 405 2.63 512 3.5-di-F₃CPh 491 3.70 513 3,5-diMeOPh 415 2.96 514

405 3.00 515

421 2.83 516

421 2.63 517

421 2.70 518

484 2.45 519

484 3.40 520

421 3.10 521

421 3.13 522

421 2.85

TABLE 21 (continued from Table 20) HPLC Ex R¹ MASS rt(min) 523

406 3.24 524

422 2.18 525

426 2.98 526

394 2.53 527

395 2.64 528

413 3.43 529

396 2.57 530

399 2.78 531

413 2.73 532

427 2.83 533

395 3.17 534

409 3.15 535

443 3.42 536

488 3.43 537

443 3.49 538

522 3.82 539

472 3.26 540

474 3.20 541

346 2.83 542

360 2.41 543

402 2.70 544

419 3.39 545

459 3.72 546

487 4.01 547

362 2.49 548

395 2.83 549

363 2.40 550

423 2.69 551

417 3.27 552

345 2.36 553

370 2.86 554

427 2.98 555

411 2.86

TABLE 22

HPLC Ex R¹ R² MASS rt(min) 556

H 356 2.42 557

H 442 2.91 558

H 372 2.51 559

H 462 2.79 560

H 356 2.35 561

H 386 2.76 562

H 356 2.41 563

H 357 2.28 564

H 386 2.33 565

H 406 2.93 566

H 460 2.69 567

H 461 2.57 568 3-MePh Me 383 3.19 569

H 381 3.56 570 3-MePh H 369 3.10 571 3-MeSO₂Ph H 433 2.79 572

H 471 2.52 573 4-MeSO₂Ph H 433 2.80 574

H 424 2.86 575

H 452 2.91 576

H 504 2.96 577

H 502 3.68 578

H 500 1.82 579

H 452 2.99 580

H 487 3.07 581

H 487 3.10 582

H 466 3.09 583

H 501 2.08

TABLE 23

Ex

MASS HPLCrt(min) 584 2-FPhNH— 2-FPhNH— 357 2.68 585 2-EtPhNH— 2-EtPhNH— 377 2.85 586 2-PrPhNH— 2-PrPhNH— 405 3.06 587 2-MeSPhNH— 2-MeSPhNH— 413 2.88 588 2-HO(CH₂)₂PhNH 2-HO(CH₂)₂PhNH 409 2.13 589 2-PhPhH 2-PhPhH 473 3.1  590

451 2.88 591

491 2.84 592 3-FPhNH— 3-FPhNH— 357 2.84 593 3-BrPhNH— 3-BrPhNH— 479 2.84 594 3-MeOPhNH— 3-MeOPhNH— 381 2.61 595 3-MeSPhNH— 3-MeSPhNH— 413 2.93 596 3-AcPhNH— 3-AcPhNH— 405 2.41 597 3-PhOPh 3-PhOPh 505 3.47 598 3-BzPhNH— 3-BzPhNH— 529 3.22 599 3-BzlOPhNH— 3-BzlOPhNH— 533 3.38 600 4-FPhNH— 4-FPhNH— 357 2.62 601 4-ClPhNH— 4-ClPhNH— 389 3.15 602 4-BrPhNH— 4-BrPhNH— 479 3.26 603 4-MeOPhNH— 4-MeOPhNH— 381 2.42 604 4-PrPhNH— 4-PrPhNH— 405 3.32 605 4-iPrPhNH— 4-iPrPhNH— 405 3.25 606 4-tBuPhNH— 4-tBuPhNH— 433 3.43 607 4-Me₂NPhNH— 4-Me₂NPhNH— 407 1.45 608 4-Et₂NPhNH— 4-Et₂NPhNH— 463 1.58 609 4-MeSPhNH— 4-MeSPhNH— 413 2.9  610 4-PhOPhNH— 4-PhOPhNH— 505 3.31 611

491 2.18 612

487 1.59 613 4-cHexPhNH— 4-cHexPhNH— 485 3.71 614 2,5-diMePhNH— 25-diMePhNH— 377 2.9  615 3,4-diMeOPhNH 3,4-diMeOPhNH 441 2.16 616 3-F-4-MePhNH— 3-F-4-MePhNH— 385 3.1  617 3,5-diMeOPhNH 3,5-diMeOPhNH 441 2.68 618

421 2.86 619

423 1.76 620

463 2.68 621

399 2.26 622

409 2.37

TABLE 24 (continued from Table 23) Ex

MASS HPLCrt(min) 623

437 2.35 624

465 2.48 625

401 3.11 626

429 3.12 627

405 3.42 628

497 3.5  629

497 3.61 630

555 3.38 631

615 3.83 632 3-MePhNH— 3-MePhNH— 349 2.89 633

553 1.87 634

619 2.57 635

458 3.11 636

515 2.37 637 2-FPhNH— PhNH— 339 2.54 638 2-ClPhNH— PhNH— 355 2.72 639 2-BrPhNH— PhNH— 399 2.74 640 2-NO₂PhNH— PhNH— 366 2.88 641 2-MeOPhNH— PhNH— 351 2.54 642 2-MePhNH— PhNH— 335 2.54 643 2-EtPhNH— PhNH— 349 2.66 644 2-PrPhNH— PhNH— 363 2.83 645 2-iPrPhNH— PhNH— 363 2.8  646 2-tBuPhNH— PhNH— 377 2.86 647 2-MeSPhNH— PhNH— 367 2.62 648 2-HO(CH₂)₂PhNH— PhNH— 365 2.31 649 2-AcPhNH— PhNH— 363 2.69 650 2-PhPhNH— PhNH— 397 2.83 651 2-BzPhNH— PhNH— 425 2.91 652

PhNH— 426 2.41 653 2-H₂NCOPhNH— PhNH— 413 2.99 654

PhNH— 436 2.85 655

PhNH— 386 2.72

TABLE 25

Ex

MASS HPLCrt (min) 656

406 2.68 657

404 2.8 658 3-FPhNH— 339 2.68 659 3-ClPhNH— 355 2.85 660 3-BrPhNH— 399 2.9 661 3-MeOPhNH— 351 2.54 662 3-MeSPhNH— 367 2.74 663 3-NO₂PhNH— 366 2.7 664 3-AcPhNH— 363 2.44 665 3-CNPhNH— 345 2.5 666 3-CF₃PhNH— 389 2.98 667 3-H₂NCOPhNH— 364 2.08 668 3-PhOPhNH— 413 3.05 669 3-BzPhNH— 425 2.86 670 3-BzlOPhNH— 427 3.03 671 4-FPhNH— 339 2.59 672 4-ClPhNH— 355 2.83 673 4-BrPhNH— 399 2.89 674 4-MeOPhNH— 351 2.47 675 4-CF₃PhNH— 389 3.05 676 4-AcPhNH— 363 2.5 677 4-NO₂PhNH— 366 2.82 678 4-H₂NSO₂PhNH— 400 2.04 679 4-PrPhNH— 363 3 680 4-iPrPhNH— 363 2.97 681 4-tBuPhNH— 377 3.07 682 4-Me₂NPhNH— 364 1.94 683 4-Et₂NPhNH— 392 1.96 684 4-MeSPhNH— 367 2.72 685 4-H₂NCOPhNH— 364 2.07 686 4-CNPhNH— 346 2.59 687 4-AcNHPhNH— 378 2.16 688 4-CNCH₂PhNH— 360 2.29 689 4-PhOPhNH— 413 3.02 690 4-BzPhNH— 425 2.95 691

483 2.17 692

406 2.34 693

404 1.95 694 4-cHexPhNH— 403 3.3 695

468 3.47 696

388 2.33

TABLE 26

Ex

MASS HPLC rt (min) 697

357 2.71 698 1,2-diClPhNH— 389 3.06 699 1,4-diClPhNH— 389 3.15 700 4-Cl-2-MePhNH— 369 2.81 701 4-CN-2-EtPhNH— 374 2.69 702 2-Bz-4-ClPhNH— 459 3.25 703 4-Et₂NSO₂-2-MeOPhNH— 486 2.76 704 2,5-diMePhNH— 349 2.69 705 2-Cl-5-MePhNH— 369 2.92 706 3,4-diMeOPhNH— 381 2.33 707 3,4-diClPhNH— 389 3.15 708 3-F-4-MePhNH— 353 2.83 709 3,5-diCF₃PhNH— 457 3.54 710 3,5-diMeOPhNH— 381 2.6 711

371 2.68 712

372 1.96 713

372 2.06 714

372 2.78 715

372 1.85 716

392 2.59 717

360 2.38 718

361 2.18 719

361 2.29 720

379 2.95 721

362 2.17 722

365 2.45 723

379 2.42 724

393 2.49 725

361 2.86 726

375 2.85

TABLE 39

(The numbers 2 to 6 in the formula above represent respective bonding positions of R³ and R⁵.) No R¹⁰¹ R³ R⁵ 190

4-Me 4-F 191

4-MeO 4-F 192

H 4-F 193

4-F 4-F 194

H 4-MeO 195

4-Me 4-F 196

4-MeO 4-F 197

H H 198

H 4-F 199

F F 200

H 4-MeO 201

4-Me 4-F 202

4-MeO 4-F 203

H 4-F 204

4-F 4-F 205

H H 206

H 4-F 207

4-F 4-F 208

H 4-MeO 209

4-Me 4-F 210

4-MeO 4-F 211

H H 212

4-F 4-F 213

H 4-MeO 214

4-Me 4-F 215

4-MeO 4-F 216

4-MeO 4-F 217

H H 218

H H 219

H 4-F 220

4-F 4-F 221

4-Me 4-F 222

4-MeO 4-F 223

H H 224

H 4-F 225

4-F 4-F 226

H 4-MeO 227

4-Me 4-F 228

4-MeO 4-F

TABLE 27

Ex

MASS HPLCrt (min) 727

390 2.44 728

451 3.31 729

409 2.98 730

409 3.06 731

438 2.96 732

440 2.67 733

468 3.16 734 3-MePhNH— 335 2.61 735

437 2.02 736

390 2.57 737

418 2.37 738

434 2.18 739

470 2.41

TABLE 28

(The numbers 2 to 6 in the formula above represent respective bonding positions of R³ and R⁵.) Ex

R³ R⁵ Salt/Solvate DATA 740

H H 2 HCl0.4 H₂O m.p.: 161-162¹H-NMR: 3.00-3.20 (2 H, m), 3.60-3.80 (2 H, m), 7.13-7.20 (2 H,m), 7.30-7.45 (4 H, m), 7.55-7.90 (6 H, m), 8.35-9.00 (3 H, m),10.45-11.00 (2 H, m)/DMSO-d₆ 741

H H HCl0.2 H₂O m.p.: 191-193¹H-NMR: 1.15-1.30 (2 H, m), 1.55-1.75 (2 H, m), 1.80-1.95 (1 H,m), 3.20-3.35 (4 H, m), 3.80-3.92 (2 H, m), 7.08-7.22 (2 H, m),7.28-7.44 (4 H, m), 7.50-7.85 (4 H, m), 8.87 (1 H, brs), 10.00-11.05(2 H, m)/DMSO-d₆ 742

H H HCl m.p.: 112-113¹H-NMR: 1.06 (6 H, s), 1.20 (3 H, d, J = 6.3 Hz), 1.27-1.65 (6 H, m),3.95-4.25 (1 H, m), 7.10-7.21 (2 H, m), 7.30-7.48 (4 H, m), 7.50-7.80(4 H, m), 8.79 (1 H, s), 10.20-11.25 (2 H, m)/DMSO-d₆ 743

4-F 4-F HCl m.p.: 191-192¹H-NMR: 4.62 (2 H, brs), 7.00-7.38 (6 H, m), 7.40-7.80 (4 H, m),8.25 (1 H, d, J = 4.8 Hz), 8.82 (1 H, brs), 9.95-10.40 (2 H, m)/DMSO-d₆ 744

H 4-F HCl m.p.: 175-177¹H-NMR: 4.63 (2 H, brs), 7.00-7.40 (7 H, m), 7.42-7.80 (4 H, m),8.21 (1 H, d, J = 5.6 Hz), 8.77 (1 H, brs), 9.84-10.44 (2 H, m)/DMSO-d₆ 745

H 4-F 2 HCl1 H₂O0.2 AcOEt m.p.: 175-177¹H-NMR: 2.74 (3 H, s), 4.76 (2 H, brs), 6.96-7.15 (2 H, m), 7.15-7.29(2 H, m), 7.36 (1 H, t, J = 7.9 Hz), 7.47 (2 H, brs), 7.71 (2 H,brs), 7.83 (1 H, d, J = 6.0 Hz), 7.88 (1 H, s), 8.72 (1 H, d, J = 6.0 Hz),8.90 (1 H, brs), 10.07 (1 H, brs), 10.31 (1 H, brs)/DMSO-d₆ 746

H 4-F 2 HCl1 H₂O0.1 AcOEt m.p.: 188-190¹H-NMR: 4.81 (2 H, brs), 4.89 (2 H, s), 6.97-7.16 (2 H, m), 7.16-7.30(2 H, m), 7.31-7.40 (1 H, m), 7.45 (2 H, brs), 7.71 (2 H, brs),7.90 (1 H, d, J = 5.9 Hz), 8.00 (1 H, s), 8.76 (1 H, d, J = 5.9 Hz), 9.06(1 H, brs), 10.19 (1 H, brs), 10.49 (1 H, brs)/DMSO-d₆ 747

H 4-F 2.1 HCl1.5 H₂O m.p.: 164-199¹H-NMR: 4.55 (2 H, brs), 6.85 (1 H, d, J = 6.9 Hz), 6.93 (1 H, s),6.98-7.15 (2 H, m), 7.15-7.30 (2 H, m), 7.30-7.40 (1 H, m), 7.53(2 H, brs), 7.71 (2 H, brs), 7.95 (1 H, d, J = 6.9 Hz), 8.14 (2 H, brs),8.80 (1 H, brs), 10.09 (1 H, brs), 10.30 (1 H, brs), 13.91 (1 H, brs)/DMSO-d₆

TABLE 29 (continued from Table 28) 748

H 4-F 1.9 HCl1.5 H₂O m.p.: 153-155¹H-NMR: 2.95 (3 H, d, J = 4.4 Hz), 4.55 (2 H, brs), 6.84 (1 H, d,J = 6.8 Hz), 6.98 (1 H, s), 6.92-7.13 (3 H, m), 7.13-7.22 (1 H, m), 7.22-7.29(1 H, m), 7.29-7.38 (1 H, m), 7.56 (2 H, brs), 7.72 (2 H, brs), 7.99(1 H, d, J = 6.8 Hz), 8.65 (1 H, brs), 8.99 (1 H, brs), 9.95 (1 H, brs), 10.11(1 H, brs), 13.60 (1 H, brs)/DMSO-d₆ 749

H 4-F 1.9 HCl1.5 H₂O m.p.: 149-151¹H-NMR: 1.18 (3 H, t, J = 7.3 Hz),.3.28-3.46 (2 H, m), 4.54 (2 H, brs),6.83 (1 H, d, J = 6.3 Hz), 6.90-7.13 (3 H, m), 7.13-7.29 (2 H, m), 7.29-7.39(1 H, m), 7.56 (2 H, brs), 7.72 (2 H, brs), 7.87 (1 H, d, J = 6.3 Hz),8.56 (1 H, brs), 8.90 (1 H, brs), 9.89 (1 H, brs), 10.12 (1 H, brs), 13.59(1 H, brs)/DMSO-d₆ 750

H 4-F 2 HCl1.5 H₂O m.p.: 149-150¹H-NMR: 0.92 (3 H, t, J = 7.4 Hz),.1.50-1.66 (2 H, m), 3.23-3.40 (2 H,m), 4.54 (2 H, brs), 6.82 (1 H, d, J = 6.9 Hz), 6.94-7.14 (3 H, m), 7.14-7.29(2 H, m), 7.29-7.40 (1 H, m), 7.56 (2 H, brs), 7.72 (2 H, brs), 7.82-7.92(1 H, m), 8.60 (1 H, brs), 8.94 (1 H, brs), 9.94 (1 H, brs), 10.07(1 H, brs), 13.62 (1 H, brs)/DMSO-d₆ 751

H 4-F 1.9 HCl0.5 H₂O m.p.: 155-157¹H-NMR: 1.31 (3 H, t, J = 6.8 Hz), 4.31 (2 H, q, J = 6.8 Hz),. 4.59 (2 H,brs), 6.87 (1 H, s), 7.03 (1 H, d, J = 5.2 Hz), 7.07-7.33 (4 H, m), 7.33-7.43(1 H, m), 7.50 (2 H, brs), 7.67 (2 H, brs), 8.14 (1 H, d, J = 5.2 Hz),9.29 (1 H, brs), 10.47 (1 H, brs), 10.83 (1 H, brs)/DMSO-d₆ 752

H 4-F 1.9 HCl1.1 H₂O m.p.: 145-147¹H-NMR: 3.87 (3 H, s), 4.58 (2 H, brs), 6.89 (1 H, brs), 6.97-7.34 (5 H,m), 7.34-7.43 (1 H, m), 7.50 (2 H, brs), 7.67 (2 H, brs), 8.16 (1 H, d,J = 5.4 Hz), 9.32 (1 H, brs), 10.50 (1 H, brs), 10.86 (1 H, brs)/DMSO-d₆ 753

H 4-F free0.1 H₂O m.p.: 134-136¹H-NMR: 3.82 (3 H, s), 4.44 (2 H, d, J = 6.3 Hz), 6.79 (1 H, d, J = 6.9 Hz),6.94 (1 H, t, J = 7.4 Hz), 7.03-7.18 (2 H, m), 7.20-7.30 (2 H, m), 7.60(1 H, brs), 7.66-7.87 (6 H, m), 8.16 (1 H, s), 8.98-9.26 (2 H, m)/DMSO-d₆ 754

H 4-F 1.8 HCl0.4 H₂O m.p.: 112-114¹H-NMR: 4.63 (2 H, brs), 7.00-7.33 (4 H, m), 7.33-7.90 (7 H, m), 8.00(1 H, dd, J = 7.8 Hz, 15.6 Hz), 9.36 (1 H, brs), 10.52 (1 H, brs), 10.97(1 H, brs)/DMSO-d₆ 755

H 4-F 2 HClH₂O m.p.: 139-140¹H-NMR: 2.80 (3 H, s), 4.96 (2 H, d, J = 4.9 Hz), 6.97-7.24 (3 H, m),7.24-7.32 (1 H, m), 7.32-7.41 (1 H, m), 7.41-7.60 (2 H, m), 7.60-7.88(4 H, m), 8.36 (1 H, t, J = 6.5 Hz), 8.89 (1 H, brs), 10.19 (1 H, brs), 10.45(1 H, brs)/DMSO-d₆ 756

H 4-F 2 HClH₂O0.3 AcOEt m.p.: 147-148¹H-NMR: 2.56 (3 H, s), 4.90 (2 H, d, J = 5.4 Hz),. 6.79-7.30 (4 H, m),7.30-7.41 (1 H, m), 7.41-7.81 (5 H, m), 7.85 (1 H, s), 8.71 (1 H, d,J = 5.8 Hz), 8.89 (1 H, brs), 10.25 (1 H, brs), 10.46 (1 H, brs)/DMSO-d₆

TABLE 30 (continued from Table 29) 757

H 4-F 1.95 HCl m.p.: 146-148¹H-NMR: 4.79 (2 H, s),. 4.81 (2 H, s),. 6.90-7.28 (4 H, m), 7.28-7.39(1 H, m), 7.40-7.80 (6 H, m), 8.15-8.33 (1 H, m), 7.95 (1 H, brs),8.48 (1 H, brs), 9.85 (1 H, brs), 9.98 (1 H, brs)/DMSO-d₆ 758

H 4-F 2 HCl0.5 H₂O m.p.: 160-162¹H-NMR: 1.45 (9 H, s), 4.57 (2 H, brs), 6.96-7.32 (6 H, m), 7.32-7.57(3 H, m), 7.67 (2 H, d, J = 7.8 Hz), 7.80 (1 H, t, J = 7.5 Hz), 9.18(1 H, brs), 9.94 (1 H, brs), 10.47 (1 H, brs), 10.86 (1 H, brs)/DMSO-d₆ 759

H 4-F 1.9 HCl0.9 H₂O0.1 AcOEt m.p.: 120-122¹H-NMR: 3.87 (3 H, s), 4.60 (2 H, brs), 6.75 (1 H, d, J = 7.8 Hz), 6.90-7.35(5 H, m), 7.40 (1 H, t, J = 7.4 Hz), 7.50 (2 H, brs), 7.61-7.80 (3 H,m), 9.34 (1 H, brs), 10.59 (1 H, brs), 11.00 (1 H, brs)/DMSO-d6 760

H 4-F 2.4 HClH₂O m.p.: 152-154¹H-NMR: 1.33 (2 H, d, J = 6.3 Hz), 4.60 (2 H, brs), 5.23 (1 H, hep,J = 6.3 Hz), 6.65 (1 H, d, J = 8.3 Hz), 6.95 (1 H, d, J = 6.9 Hz), 7.01-7.33(4 H, m), 7.33-7.58 (3 H, m), 7.58-7.80 (3 H, m), 9.22 (1 H, brs),10.53 (1 H, brs), 10.87 (1 H, brs)/DMSO-d₆ 761

H 4-F 2 HCl0.3 H₂O0.1 AcOEt m.p.: 161-163¹H-NMR: 4.79 (2 H, brs), 7.00-7.45 (6 H, m), 7.48 (2 H, brs), 7.71(2 H, brs), 8.86 (2 H, d, J = 4.9 Hz), 9.54 (1 H, brs), 10.57 (1 H, brs),11.17 (1 H, brs)/DMSO-d6 762

H 4-F 1.95 HCl1.5 H₂O m.p.: 158-160¹H-NMR: 4.57 (2 H, brs), 6.97 (1 H, d, J = 6.4 Hz), 7.01-7.32 (4 H, m),7.32-7.42 (1 H, m), 7.71 (2 H, brs), 7.95 (2 H, brs), 8.41 (1 H, d,J = 6.4 Hz), 8.53 (2 H, brs), 8.84 (1 H, brs), 10.13 (1 H, brs), 10.40(1 H, brs)/DMSO-d₆ 763

H 4-F HCl m.p.: 140-141¹H-NMR: 4.49 (2 H, s), 4.58 (2 H, brs), 7.04-7.27 (5 H, m), 7.27-7.42(4 H, m), 7.59 (2 H, brs), 7.66 (2 H, brs), 9.00 (1 H, brs), 10.30(1 H, brs), 10.52 (1 H, brs)/DMSO-d₆ 764

H 4-F HCl0.5 H₂O m.p.: 144-148¹H-NMR: 4.57 (2 H, brs), 6.26-6.48 (2 H, m), 7.05-7.20 (3 H, m),7.30-7.40 (2 H, m), 7.50-7.80 (5 H, m), 8.79 (1 H, brs), 9.95-10.70(2 H, m)/DMSO-d₆ 765

H 4-F 1.9 HClH₂O m.p.: 124-125¹H-NMR: 4.74 (2 H, brs), 7.04-7.28 (3 H, m), 7.28-7.45 (2 H, m),7.45-8.00 (5 H, m), 9.17 (1 H, s), 9.40 (1 H, brs), 10.64 (1 H, brs),11.06 (1 H, brs)/DMSO-d₆ 766

H 4-F 2 HCl m.p.: 122-123¹H-NMR: 4.86 (2 H, brs), 7.00-7.17 (2 H, m), 7.17-7.24 (1 H, m),7.24-7.32 (1 H, m), 7.32-7.42 (1 H, m), 7.57 (2 H, brs), 7.62-7.76(3 H, m), 7.80 (1 H, d, J = 3.4 Hz), 9.02 (1 H, brs), 10.20 (1 H, brs),10.39 (1 H, brs)/DMSO-d6 767

H 4-F free m.p.: 214-215¹H-NMR: 3.69 (3 H, s), 4.69 (2 H, d, J = 6.4 Hz), 5.35 (2 H, s), 6.84(2 H, d, J = 8.5 Hz), 6.90-6.98 (1 H, m), 6.98-7.13 (3 H, m), 7.18 (2 H,d, J = 8.5 Hz), 7.77 (2 H, brs), 7.87 (1 H, s), 9.09 (1 H, s), 9.13 (1 H, s)/DMSO-d₆

TABLE 31 (continued from Table 30) 768

H 4-F HCl m.p.: 209-211¹H-NMR: 4.86 (2 H, brs), 6.95-7.17 (3 H, m), 7.17-7.30 (2 H, m),7.30-7.40 (1 H, m), 7.49 (2 H, brs), 7.69 (2 H, brs), 8.76 (1 H, brs),10.15 (1 H, brs), 10.36 (1 H, brs)/DMSO-d₆ 769

H 4-F 1.8 HCl0.4 H₂O m.p.: 212-214¹H-NMR: 4.99 (2 H, brs), 6.92-7.33 (4 H, m), 7.33-7.47 (2 H, m),7.47-7.60 (3 H, m), 7.69 (2 H, brs), 8.01 (1 H, d, J = 7.9 Hz), 8.09(1 H, d, J = 7.9 Hz), 9.38 (1 H, brs), 10.38 (1 H, brs), 10.68 (1 H,brs)/DMSO-d₆ 770

H 4-F HCl0.5 H₂O m.p.: 160-162¹H-NMR: 4.35 (2 H, d, J = 4.9 Hz), 7.02-7.10 (1 H, m), 7.16 (2 H, t,J = 7.8 Hz), 7.32 (2 H, t, J = 7.8 Hz), 7.72 (4 H, brs), 8.28 (1 H, brs),9.93 (2 H, brs),/DMSO-d6 771 MeO(CH₂)₂NH— H 4-F HCl m.p.: 179-181 ¹H-NMR: 3.29 (3 H, s), 3.40-3.60 (4 H, m), 7.10-7.25 (3 H, m), 7.26-7.42 (2 H, m), 7.50-7.84 (4 H, m), 8.60 (1 H, brs), 10.15-11.00 (2 H, m)/DMSO-d₆ 772

H 4-F 1.3 HCl0.2 H₂O m.p.: 160-162¹H-NMR: 3.56 (2 H, s), 3.77-3.90 (2 H, m), 3.90-4.05 (2 H, m),5.06 (1 H, s), 7.07-7.27 (3 H, m), 7.27-7.44 (2 H, m), 7.64 (4 H,brs), 8.73 (1 H, brs), 10.47 (1 H, brs), 10.77 (1 H, brs)/DMSO-d₆ 773 HO(CH₂)₂NH— H 4-F HCl m.p.: 209-211 ¹H-NMR: 3.38-3.48 (2 H, m), 3.58 (2 H, t, J = 5.4 Hz), 4.16 (1 H, brs), 7.05-7.26 (3 H, m), 7.27-7.43 (2 H, m), 7.48-7.80 (4 H, m), 8.45 (1 H, brs), 10.05-10.75 (2 H, m)/DMSO-d₆ 774 HO(CH₂)₃NH— H 4-F HCl m.p.: 188-189 0.1 H₂O ¹H-NMR: 1.65-1.80 (2 H, m), 3.37-3.56 (4 H, m), 4.15 (1 H, brs), 7.05-7.26 (3 H, m), 7.27-7.43 (2 H, m), 7.45-7.85 (4 H, m), 8.57 (1 H, brs), 10.05-10.75 (2 H, m)/DMSO-d₆ 775 HO(CH₂)₄NH— H 4-F HCl m.p.: 185-186 ¹H-NMR: 1.43-1.53 (2 H, m), 1.55-1.65 (2 H, m), 3.30-3.48 (4 H, m), 4.04 (1 H, brs), 7.05-7.26 (3 H, m), 7.27-7.42 (2 H, m), 7.50-7.80 (4 H, m), 8.58 (1 H, brs), 9.95-10.75 (2 H, m)/DMSO-d₆ 776 HO(CH₂)₅NH— H 4-F HCl m.p.: 178-180 ¹H-NMR: 1.34-1.50 (4 H, m), 1.53-1.60 (2 H, m), 3.30-3.42 (4 H, m), 4.00 (1 H, brs), 7.07-7.24 (3 H, m), 7.33-7.40 (2 H, m), 7.50-7.80 (4 H, m), 8.58 (1 H, brs), 10.05-10.75 (2 H, m)/DMSO-d₆ 777 HO(CH₂)₂O(CH₂)₂NH— H 4-F HCl m.p.: 141-142 ¹H-NMR: 3.43-3.60 (8 H, m), 3.92 (1 H, brs), 7.05-7.25 (3 H, m), 7.27-7.43 (2 H, m), 7.50-7.80 (4 H, m), 8.37 (1 H, brs), 9.95-10.60 (2 H, m)/DMSO-d₆ 778

H 4-F HCl m.p.: 192-194¹H-NMR: 1.17 (3 H, d, J = 6.9 Hz), 3.47 (2 H, d, J = 5.4 Hz), 4.07(1 H, brs), 7.05-7.28 (3 H, m), 7.28-7.45 (2 H, m), 7.66 (4 H, brs),8.56 (1 H, brs), 10.45 (1 H, brs), 10.84 (1 H, brs)/DMSO-d₆ 779

H 4-F HCl m.p.: 193-195¹H-NMR: 1.17 (3 H, d, J = 6.9 Hz), 3.47 (2 H, d, J = 5.4 Hz), 4.07(1 H, brs), 7.05-7.28 (3 H, m), 7.28-7.45 (2 H, m), 7.66 (4 H, brs),8.53 (1 H, brs), 10.43 (1 H, brs), 10.80 (1 H, brs)/DMSO-d₆

TABLE 32 (continued from Table 31) 780

H 4-F HCl m.p.: 199-201¹H-NMR: 0.92 (3 H, d, J = 7.2 Hz), 1.42-1.58 (1 H, m), 1.58-1.74 (1 H, m),3.50 (2 H, d, J = 5.4 Hz), 3.91 (1 H, brs), 7.05-7.28 (3 H, m), 7.28-7.45(2 H, m), 7.66 (4 H, brs), 8.58 (1 H, brs), 10.46 (1 H, brs), 10.88 (1 H, brs)/DMSO-d₆ 781

H 4-F HCl m.p.: 199-201¹H-NMR: 0.92 (3 H, d, J = 6.8 Hz), 1.41-1.58 (1 H, m), 1.58-1.75 (1 H, m),3.50 (2 H, d, J = 4.9 Hz), 3.91 (1 H, brs), 7.05-7.29 (3 H, m), 7.29-7.47(2 H, m), 7.66 (4 H, brs), 8.50 (1 H, brs), 10.41 (1 H, brs), 10.77 (1 H, brs)/DMSO-d₆ 782

H 4-F HCl m.p.: 205-207¹H-NMR: 0.95 (6 H, d, J = 6.3 Hz), 1.87-2.04 (1 H, m), 3.45-3.64 (2 H, m),3.87 (1 H, brs), 7.05-7.29 (3 H, m), 7.29-7.45 (2 H, m), 7.67 (4 H, brs),8.68 (1 H, brs), 10.47 (1 H, brs), 11.03 (1 H, brs)/DMSO-d6 783

H 4-F HCl m.p.: 185-186¹H-NMR: 0.91 (6 H, d, J = 6.3 Hz), 1.33-1.54 (2 H, m), 1.57-1.73 (1 H, m),3.38-3.55 (2 H, m), 4.10 (1 H, brs), 7.07-7.28 (3 H, m), 7.28-7.45 (2 H,m), 7.66 (4 H, brs), 8.53 (1 H, brs), 10.40 (1 H, brs), 10.85 (1 H, brs)/DMSO-d6 784

H 4-F HCl m.p.: 161-162¹H-NMR: 1.70-1.83 (1 H, m), 1.83-1.95 (1 H, m), 2.04 (3 H, s), 2.45-2.62(2 H, m), 3.51 (2 H, d, J = 4.4 Hz), 4.10 (1 H, brs), 7.05-7.27 (3 H,m), 7.27-7.44 (2 H, m), 7.66 (4 H, brs), 8.44 (1 H, brs), 10.31 (1 H, brs),10.64 (1 H, brs)/DMSO-d6 785

H 4-F HCl m.p.: 173-174¹H-NMR: 3.70 (2 H, d, J = 5.8 Hz), 5.06 (1 H, brs), 7.04-7.19 (2 H, m),7.19-7.33 (3 H, m), 7.33-7.45 (5 H, m), 7.51 (2 H, brs), 7.67 (2 H, brs),8.92 (1 H, brs), 10.18 (1 H, brs), 10.50 (1 H, brs)/DMSO-d₆ 786

H 4-F HCl m.p.: 174-175¹H-NMR: 3.71 (2 H, d, J = 4.9 Hz), 5.05 (1 H, brs), 7.06-7.20 (2 H, m),7.20-7.34 (3 H, m), 7.34-7.46 (5 H, m), 7.50 (2 H, brs), 7.68 (2 H, brs),9.18 (1 H, brs), 10.34 (1 H, brs), 10.79 (1 H, brs)/DMSO-d₆ 787

H 4-F HCl m.p.: 179-181¹H-NMR: 1.81-1.95 (1 H, m), 1.96-2.09 (1 H, m), 3.36-3.53 (2 H, m),5.16 (1 H, brs), 7.04-7.38 (5 H, m), 7.38-7.45 (5 H, m), 7.53 (2 H, d,J = 5.8 Hz), 7.66 (2 H, brs), 9.13 (1 H, brs), 10.24 (1 H, brs), 10.58(1 H, brs)/DMSO-d6 788

H 4-F HCl m.p.: 154-156¹H-NMR: 2.80-2.97 (1 H, m), 3.04 (1 H, dd, J = 8.8, 16.1 Hz), 3.58 (3 H,s), 5.49 (1 H, brs), 7.04-7.24 (3 H, m), 7.24-7.40 (5 H, m), 7.43 (2 H, s),7.58 (2 H, d, J = 5.8 Hz), 7.67 (2 H, brs), 8.92 (1 H, brs), 10.14 (1 H, brs),10.35 (1 H, brs),/DMSO-d6

TABLE 33 (continued from Table 32) 789 MeONH— H 4-F HCl m.p.: 140-141 0.8 H₂O ¹H-NMR: 3.78 (3 H, s), 7.05-7.28 (3 H, m), 7.28-7.43 (2 H, m), 7.67 (4 H, brs), 10.53 (2 H, brs), 11.79 (1 H, brs)/DMSO-d₆ 790 EtONH— H 4-F HCl m.p.: 141-143 0.3 H₂O ¹H-NMR: 1.32 (3 H, t, J = 6.9 Hz), 4.01 (2 H, q, J = 6.9 Hz), 7.06-7.26 (3 H, 0.1 AcO m), 7.29-7.44 (2 H, m), 7.68 (4 H, brs), 10.34 (2 H, brs), 11.98 (1 H, brs)/ Et DMSO-d₆ 791 Me₂NNH— H 4-F HCl m.p.: 154-156 ¹H-NMR: 2.64 (6 H, s), 7.10-7.30 (3 H, m), 7.30-7.46 (2 H, m), 7.52 (2 H, brs), 7.72 (2 H, brs), 10.41 (1 H, brs), 10.97 (1 H, brs), 11.88 (1 H, brs)/ DMSO-d₆ 792 BuNHNH— H 4-F HCl m.p.: 208-209 ¹H-NMR: 0.91 (3 H, brs), 1.23-1.40 (2 H, m), 1.60-1.77 (2 H, m), 3.76 (2 H, brs), 7.05-7.27 (3 H, m), 7.27-7.45 (2 H, m), 7.45-7.90 (5 H, m), 9.99-11.20 (3 H, m)/DMSO-d₆ 793 HO(CH₂)₂NHNH— H 4-F 2.5 HCl m.p.: 208-209 0.6 H₂O ¹H-NMR: 3.74 (1 H, t, J = 5.4 Hz), 3.86 (4 H, brs), 7.05-7.28 (3 H, m), 7.28-7.45 (2 H, m), 7.45-7.90 (5 H, m), 10.37 (2 H, brs), 10.99 (1 H, brs)/DMSO-d₆ 794

H 4-F 2 HCl0.5 H₂O m.p.: 184-187¹H-NMR: 1.10-1.25 (9 H, m), 1.50-1.80 (4 H, m), 2.90-3.15 (6 H, m),4.02-4.08 (1 H, m), 7.05-7.25 (3 H, m), 7.30-7.42 (2 H, m), 7.50-7.80(4 H, m), 8.59 (1 H, brs), 10.05-10.80 (2 H, brs)/DMSO-d₆ 795

4-Me 4-F HCl m.p.: 201-204¹H-NMR: 2.20-2.35 (3 H, m), 4.62 (2 H, brs), 5.56 (1 H, brs), 6.95-7.80(10 H, m), 8.21 (1 H, d, J = 5.4 Hz), 8.86 (1 H, brs), 9.80-10.75 (2 H, m)/DMSO-d₆ 796

4-MeO 4-F HCl m.p.: 212-214¹H-NMR: 3.70-3.77 (3 H, m), 4.50-4.75 (3 H, m), 6.70-6.98 (2 H, m),7.02-7.78 (10 H, m), 8.21 (1 H, d, J = 4.9 Hz), 8.73 (1 H, brs), 9.86-10.38(2 H, m)/DMSO-d₆ 797

4-Cl 4-F HCl m.p.: 214-215¹H-NMR: 4.10 (1 H, brs), 4.61 (2 H, brs), 6.98-7.42 (6 H, m), 7.43-7.85(4 H, m), 8.21 (1 H, d, J = 5.3 Hz), 8.49 (1 H, brs), 9.60-10.50 (2 H, m)/DMSO-d₆ 798

4-CF₃ 4-F HCl0.2 H₂O m.p.: 210-213¹H-NMR: 4.45-5.10 (3 H, m), 6.80-7.24 (3 H, m), 7.30-7.39 (1 H, m),7.45-7.85 (5 H, m), 7.90-8.05 (1 H, m), 8.21 (1 H, d, J = 5.4 Hz), 8.45-8.72(1 H, m), 9.70-10.50 (2 H, m)/DMSO-d₆ 799

3-F 4-F HCl m.p.: 213-215¹H-NMR: 4.17 (1 H, brs), 4.55-4.70 (2 H, m), 6.75-6.90 (1 H, m), 7.00-7.90(9 H, m), 8.16-8.22 (1 H, m), 8.44 (1 H, brs), 9.55-10.20 (2 H, m)/DMSO-d₆ 800

3-Me 4-F HCl m.p.: 195-197¹H-NMR: 2.10-2.35 (3 H, m), 4.64 (2 H, brs), 5.76 (1 H, brs), 6.80-7.00(1 H, m), 7.01-7.80 (9 H, m), 8.21 (1 H, d, J = 4.9 Hz), 8.87 (1 H, brs),9.90-10.65 (2 H, m)/DMSO-d₆ 801

3-MeO 4-F HCl m.p.: 174-175¹H-NMR: 3.60-3.80 (3 H, m), 4.50-4.74 (2 H, m), 5.81 (1 H, brs), 6.57-6.78(1 H, m), 7.00-7.80 (9 H, m), 8.21 (1 H, d, J = 3.9 Hz), 8.89 (1 H,brs), 9.90-10.70 (2 H, m)/DMSO-d₆

TABLE 34 (continued from Table 33) 802

H 4-Cl HCl m.p.: 179-181¹H-NMR: 4.64 (2 H, brs), 6.95-7.42 (7 H, m), 7.45-7.85(4 H, m), 8.21 (1 H, d, J = 4.9 Hz), 8.40-8.90 (1 H, m), 9.70-10.40(2 H, m)/DMSO-d₆ 803

H 4-Cl HCl m.p.: 187-188¹H-NMR: 4.58 (2 H, brs), 6.30-6.50 (2 H, m), 7.10-7.18(1 H, m), 7.30-7.44 (4 H, m), 7.52-7.80 (5 H, m), 8.95(1 H, brs), 10.10-10.80 (2 H, m)/DMSO-d₆ 804

H 4-Me HCl0.2 H₂O m.p.: 176-177¹H-NMR: 1.95 (2 H, d, J = 17), 4.62 (2 H, brs), 6.98-7.78(11 H, m), 7.42-7.80 (4 H, m), 8.21 (1 H, d, J = 5.4 Hz), 8.79(1 H, brs). 9.85-10.50 (2 H, m)/DMSO-d₆ 805

H 4-Me HCl m.p.: 173-174¹H-NMR: 2.29 (3 H, d, J = 4.3 Hz), 4.58 (2 H, brs), 6.25-6.55(2 H, m), 7.05-7.20 (3 H, m), 7.28-7.42 (2 H, m), 7.43-7.75(5 H, m), 9.11 (1 H, brs), 10.20-11.00 (2 H, m)/DMSO-d₆ 806

H 4-MeO HCl0.1 H₂O m.p.: 176-177¹H-NMR: 3.75 (3 H, d, J = 12.7), 4.64 (2 H, brs), 6.70-7.00(2 H, m), 7.02-7.78 (9 H, m), 8.21 (1 H, d, J = 5.3 Hz), 9.08(1 H, brs), 9.95-10.75 (2 H, m)/DMSO-d₆ 807

H 4-MeO HCl m.p.: 145-148¹H-NMR: 3.76 (3 H, d, J = 2.5 Hz), 4.58 (2 H, brs), 6.20-6.54(2 H, m), 6.90-6.98 (2 H, m), 7.05-7.18 (1 H, m), 7.25-7.42(2 H, m), 7.43-7.75 (5 H, m), 9.05 (1 H, brs), 10.05-10.85(2 H, m)/DMSO-d₆ 808 MeO(CH₂)₂NH— H 4-MeO 1.4 HCl m.p.: 169-170 ¹H-NMR: 3.29 (3 H, s), 3.45-3.63 (4 H, m), 3.73-3.80 (3 H, m), 6.85-7.03 (2 H, m), 7.05-7.22 (1 H, m), 7.25-7.80 (6 H, m), 8.83 (1 H, brs), 10.15-11.20 (2 H, m)/DMSO-d₆ 809

H 4-CF₃ HCl0.1 H₂O m.p.: 178-180¹H-NMR: 4.64 (2 H, brs), 6.98-7.42 (5 H, m), 7.45-8.04(7 H, m), 8.21 (1 H, d, J = 5.4 Hz), 8.46-8.75 (1 H, m), 9.73-10.40(2 H, m)/DMSO-d₆ 810

H 4-CF₃ HCl m.p.: 157-159¹H-NMR: 4.59 (2 H, brs), 6.32-6.46 (2 H, m), 7.05-7.16(1 H, m), 7.30-7.40 (2 H, m), 7.60-7.75 (5 H, m), 7.88-8.04(2 H, m), 8.60-9.00 (1 H, m), 10.05-10.70 (2 H, m)/DMSO-d₆ 811

H 3-F HCl m.p.: 204-206¹H-NMR: 4.54-4.70 (2 H, m), 5.95 (1 H, brs), 6.76-6.92(1 H, m), 6.98-7.95 (10 H, m), 8.15-8.25 (1 H, m), 8.60(1 H, brs), 9.70-10.40 (2 H, m)/DMSO-d₆ 812

H 3-Me HCl0.1 H₂O m.p.: 184-185¹H-NMR: 2.15-2.35 (3 H, m), 4.65 (2 H, brs), 6.85-7.00(2 H, m), 7.03-7.80 (9 H, m), 8.22 (1 H, d, J = 4.8 Hz), 8.99(1 H, brs), 10.05-10.70 (2 H, m)/DMSO-d₆ 813

H 3-Me HCl m.p.: 144-147¹H-NMR: 2.25-2.35 (3 H, m), 4.59 (2 H, brs), 6.30-6.50(2 H, m), 6.91-6.98 (1 H, m), 7.10-7.25 (2 H, m), 7.30-7.75(7 H, m), 8.99 (1 H, brs), 10.10-10.75 (2 H, m)/DMSO-d₆

TABLE 35 (continued from Table 34) 814

H 3,4-diF HCl m.p.: 199-202¹H-NMR: 4.54-4.72 (2 H, m), 6.18 (1 H, brs), 6.95-8.15 (10 H,m), 8.21 (1 H, d, J = 4.9 Hz), 8.40-9.00 (1 H, m), 9.70-10.50(2 H, m)/DMSO-d₆ 815

H 4-F, 3-Me HCl m.p.: 190-191¹H-NMR: 2.05-2.30 (3 H, m), 4.50-4.70 (2 H, m), 6.95-7.75(10 H, m), 8.21 (1 H, d, J = 4.9 Hz), 8.82 (1 H, brs), 9.85-10.50(2 H, m)/DMSO-d₆ 816

H 4-F 0.9 HClH₂O m.p.: 172-174¹H-NMR: 4.39 (2 H, brs), 6.61 (1 H, d, J = 9.3 Hz), 7.05-7.29(3 H, m), 7.29-7.44 (2 H, m), 7.44-7.89 (7 H, m), 9.19 (1 H,brs), 10.61 (1 H, brs), 10.88 (1 H, brs)/DMSO-d₆ 817

H 4-F 1.6 HCl1.5 H₂O m.p.: 157-158¹H-NMR: 4.47 (2 H, brs), 6.45 (1 H, d, J = 6.9 Hz), 6.54 (1 H, s),7.04-7.26 (4 H, m), 7.26-7.34 (1 H, m), 7.34-7.44 (1 H, m),7.54 (2 H, brs), 7.58 (1 H, d, J = 6.9 Hz), 7.68 (2 H, brs), 9.19(1 H, brs), 10.45 (1 H, brs), 10.77 (1 H, brs)/DMSO-d6 818

H 4-F 1.6 HCl0.5 H₂O m.p.: 157-158¹H-NMR: 4.47 (2 H, brs), 6.36 (1 H, s), 6.44 (1 H, d, J = 8.8 Hz),7.14-7.26 (3 H,.m), 7.26-7.34 (1 H, m), 7.34-7.43 (1 H, m),7.43-7.60 (4 H, m), 7.68 (2 H, brs), 8.99 (1 H, brs), 10.41 (1 H,brs), 10.74 (1 H, brs)/DMSO-d6 819

H 4-F 2 HCl0.8 H₂O m.p.: 164-165¹H-NMR: 4.60 (2 H, d, J = 5.4 Hz), 6.78 (1 H, d, J = 6.9 Hz), 6.90(1 H, d, J = 8.8 Hz), 6.95-7.23 (3 H, m), 7.23-7.40 (2 H, m), 7.57(2 H, brs), 7.70 (2 H, brs), 7.82-7.95 (1 H, m), 8.19 (2 H, brs),8.55 (1 H, brs), 10.11 (2 H, brs), 14.24 (1 H, brs)/DMSO-d₆ 820

H 4-F free m.p.: 223-225¹H-NMR: 4.74 (2 H, brs), 7.00-7.26 (4 H, m), 7.26-7.44 (2 H,m), 7.54 (2 H, brs), 7.68 (3 H, brs), 8.79 (1 H, s), 8.97 (1 H,brs), 10.35 (1 H, brs), 10.61 (1 H, brs)/DMSO-d₆ 821

H 4-F 2 HCl0.5 H₂O m.p.: 202-203¹H-NMR: 4.63 (2 H, brs), 7.03-7.26 (3 H, m), 7.26-7.45 (2 H,m), 7.62 (5 H, brs), 8.96 (1 H, brs), 9.09 (1 H, s), 10.51 (2 H,brs), 14.65 (2 H, brs)/DMSO-d₆

TABLE 36

(The numbers 2 to 6 in the formula above represent respective bonding positions of R³ and R⁵.) No R¹⁰¹ R³ R⁵ 1 3-FPy-2-yl H H 2 3-FPy-2-yl H 4-F 3 3-FPy-2-yl 4-F 4-F 4 3-FPy-2-yl H 4-MeO 5 3-FPy-2-yl 4-Me 4-F 6 3-FPy-2-yl 4-MeO 4-F 7 4-FPy-2-yl H H 8 4-FPy-2-yl H 4-F 9 4-FPy-2-yl 4-F 4-F 10 4-FPy-2-yl H 4-MeO 11 4-FPy-2-yl 4-Me 4-F 12 4-FPy-2-yl 4-MeO 4-F 13 5-FPy-2-yl H H 14 5-FPy-2-yl H 4-F 15 5-FPy-2-yl 4-F 4-F 16 3-FPy-4-yl 4-F 4-F 17 3-FPy-4-yl H 4-MeO 18 3-FPy-4-yl 4-Me 4-F 19

H H 20

4-F 4-F 21

H 4-MeO 22

4-Me 4-F 23

4-MeO 4-F 24

H 4-MeO 25

4-Me 4-F 26

4-MeO 4-F 27 5-FPy-2-yl H 4-MeO 28 5-FPy-2-yl 4-Me 4-F 29 5-FPy-2-yl 4-MeO 4-F 30 6-FPy-2-yl H H 31 6-FPy-2-yl 4-F 4-F 32 6-FPy-2-yl H 4-MeO 33 6-FPy-2-yl 4-Me 4-F 34 6-FPy-2-yl 4-MeO 4-F 35 5-FPy-3-yl H H 36 5-FPy-3-yl H 4-F 37 5-FPy-3-yl 4-F 4-F 38 5-FPy-3-yl H 4-MeO 39 5-FPy-3-yl 4-Me 4-F 40 5-FPy-3-yl 4-MeO 4-F 41 2-FPy-3-yl H H 42 3-FPy-4-yl 4-MeO 4-F 43 3-FPy-4-yl H H 44 3-FPy-4-yl H 4-F 45

H H 46

H 4-F 47

4-F 4-F 48

H 4-MeO 49

4-Me 4-F 50

H H 51

H 4-F 52

4-F 4-F 53 2-FPy-3-yl H 4-F 54 2-FPy-3-yl 4-F 4-F 55 2-FPy-3-yl H 4-MeO 56 2-FPy-3-yl 4-Me 4-F 57 2-FPy-3-yl 4-MeO 4-F 58 4-FPy-3-yl H H 59 4-FPy-3-yl H 4-F 60 4-FPy-3-yl 4-F 4-F 61 4-FPy-3-yl H 4-MeO 62 4-FPy-3-yl 4-Me 4-F 63 4-FPy-3-yl 4-MeO 4-F 64 6-FPy-3-yl H H 65 6-FPy-3-yl H 4-F 66 6-FPy-3-yl 4-F 4-F 67 6-FPy-3-yl H 4-MeO 68 6-FPy-3-yl 4-Me 4-F 69 6-FPy-3-yl 4-MeO 4-F 70 2-FPy-4-yl H H 71

4-MeO 4-F 72

H H 73

H 4-F 74

4-F 4-F 75

H 4-MeO 76

4-Me 4-F 77

4-MeO 4-F 78

H H

TABLE 37

(The numbers 2 to 6 in the formula above represent respective bonding positions of R³ and R⁵.) No R¹⁰¹ R³ R⁵ 79

H 4-F 80

4-F 4-F 81

H 4-MeO 82

4-Me 4-F 83

4-MeO 4-F 84

H H 85

H 4-F 86

F F 87

H 4-MeO 88

4-Me 4-F 89

4-MeO 4-F 90

H H 91

H 4-F 92

4-F 4-F 93

H 4-MeO 94

4-Me 4-F 95

4-MeO 4-F 96

H H 97

4-F 4-F 98

H 4-MeO 99

4-Me 4-F 100

4-MeO 4-F 101

H H 102

H 4-F 103

4-F 4-F 104

4-Me 4-F 105

4-MeO 4-F 106

H H 107

H 4-F 108

4-F 4-F 109

H 4-MeO 110

4-Me 4-F 111

4-MeO 4-F

TABLE 38

(The numbers 2 to 6 in the formula above represent respective bonding positions of R³ and R⁵.) No R¹⁰¹ R³ R⁵ 112 3-FPy-2-yl H H 113 3-FPy-2-yl H 4-F 114 3-FPy-2-yl 4-F 4-F 115 3-FPy-2-yl H 4-MeO 116 3-FPy-2-yl 4-Me 4-F 117 3-FPy-2-yl 4-MeO 4-F 118 4-FPy-2-yl H H 119 4-FPy-2-yl H 4-F 120 4-FPy-2-yl 4-F 4-F 121 4-FPy-2-yl H 4-MeO 122 4-FPy-2-yl 4-Me 4-F 123 4-FPy-2-yl 4-MeO 4-F 124 5-FPy-2-yl H H 125 5-FPy-2-yl H 4-F 126 5-FPy-2-yl 4-F 4-F 127 3-FPy-4-yl 4-F 4-F 128 3-FPy-4-yl H MeO 129 3-FPy-4-yl 4-Me 4-F 130 2-FPy-4-yl H H 131 2-FPy-4-yl H 4-F 132

H H 133

4-F 4-F 134

H 4-MeO 135

4-Me 4-F 136

4-MeO 4-F 137

H 4-MeO 138 5-FPy-2-yl H 4-MeO 139 5-FPy-2-yl 4-Me 4-F 140 5-FPy-2-yl 4-MeO 4-F 141 6-FPy-2-yl H H 142 6-FPy-2-yl 4-F 4-F 143 6-FPy-2-yl H 4-MeO 144 6-FPy-2-yl 4-Me 4-F 145 6-FPy-2-yl 4-MeO 4-F 146 5-FPy-3-yl H H 147 5-FPy-3-yl H 4-F 148 5-FPy-3-yl 4-F 4-F 149 5-FPy-3-yl H 4-MeO 150 5-FPy-3-yl 4-Me 4-F 151 5-FPy-3-yl 4-MeO 4-F 152 2-FPy-3-yl H H 153 3-FPy-4-yl 4-MeO 4-F 154 3-FPy-4-yl H H 155 3-FPy-4-yl H 4-F 156 2-FPy-4-yl 4-F 4-F 157 2-FPy-4-yl H 4-F 158

H H 159

H 4-F 160

4-F 4-F 161

H 4-MeO 162

4-Me 4-F 163

H H 164 2-FPy-3-yl H 4-F 165 2-FPy-3-yl 4-F 4-F 166 2-FPy-3-yl H 4-MeO 167 2-FPy-3-yl 4-Me 4-F 168 2-FPy-3-yl 4-MeO 4-F 169 4-FPy-3-yl H H 170 4-FPy-3-yl H 4-F 171 4-FPy-3-yl 4-F 4-F 172 4-FPy-3-yl H 4-MeO 173 4-FPy-3-yl 4-Me 4-F 174 4-FPy-3-yl 4-MeO 4-F 175 6-FPy-3-yl H H 176 6-FPy-3-yl H 4-F 177 6-FPy-3-yl 4-F 4-F 178 6-FPy-3-yl H 4-MeO 179 6-FPy-3-yl 4-Me 4-F 180 6-FPy-3-yl 4-MeO 4-F 181 2-FPy-4-yl H H 182 2-FPy-4-yl 4-Me 4-F 183 2-FPy-4-yl 4-MeO 4-F 184

4-MeO 4-F 185

H H 186

H 4-F 187

4-F 4-F 188

H 4-MeO 189

4-Me 4-F 

1. An anti-dementia agent which comprises a substance having BEC 1 potassium channel inhibitory action as the active ingredient.
 2. The anti-dementia agent wherein the substance having BEC 1 potassium channel inhibitory action is a 2,4,6-triamino-1,3,5-triazine derivative represented by a formula (I) or a pharmaceutically acceptable salt thereof

(symbols in the formula are as follows R¹ and R²: the same or different from each other, and each represents H, OH, an alkyl-O—, an aryl-CO—, H₂N, an alkyl-NH which may be substituted with OH, an (alkyl)₂N, a hydrocarbon radical which may be substituted or a hetero ring which may be substituted, or R¹, R² and the adjacent N may together form a nitrogen-containing hetero ring and said ring may be substituted, R³, R⁴, R⁵ and R⁶: the same or different from one another, and each represents (i) H, (ii) CN, (iii) NO₂, (iv) a halogen, (v) a lower alkyl which may be substituted with (1) CN, (2) a halogen or (3) OH, (vi) a cycloalkyl, (vii) an aryl which may be substituted with a lower alkyl, (ix) a hetero ring which may be substituted with a lower alkyl, (x) R⁷R⁸N— (R⁷ and R⁸: the same or different from each other, and each represents (1) H or (2) a lower alkyl which may be substituted with an aryl or R⁹—O—CO— (R⁹: (1) H or a lower alkyl which may be substituted with an aryl), (xi) R¹⁰-T¹- (R¹⁰: (1) H, (2) a lower alkyl which may be substituted with an aryl, an HO—C₁₋₁₀ alkylene-O— or HO or (3) an aryl, T¹: O or S), or (xii) R¹¹-T²- (R¹¹: (1) OH, (2) R⁷R⁸N—, (3) a lower alkyl-O—, (4) a lower alkyl, (5) an aryl or (6) a hetero ring, (T²: CO or SO₂)), further, R³, R⁴ and the adjacent C, or R⁵, R⁶ and the adjacent C, may together form a hetero ring or cyclic hydrocarbon ring, and the ring may be condensed with a benzene ring).
 3. A BEC 1 potassium channel described in SEQ ID NO:2 inhibitor, which comprises, as the active ingredient, a 2,4,6-triamino-1,3,5-triazine derivative represented by the formula (I) or a pharmaceutically acceptable salt thereof.
 4. A 2,4,6-triamino-1,3,5-triazine derivative represented by a formula (II) or a pharmaceutically acceptable salt thereof

(symbols in the formula are as follows R¹ and R²: the same or different from each other, and each represents H, OH, an alkyl-O—, an aryl-CO—, H₂N, an alkyl-NH which may be substituted with OH, an (alkyl)₂N, a hydrocarbon radical which may be substituted or a hetero ring which may be substituted, or R¹, R² and the adjacent N may together form a nitrogen-containing hetero ring and said ring may be substituted, R³, R⁴, R⁵ and R⁶: the same or different from one another, and each represents (i) H, (ii) CN, (iii) NO₂, (iv) a halogen, (v) a lower alkyl which may be substituted with (1) CN, (2) a halogen or (3) OH, (vi) a cycloalkyl, (vii) an aryl which may be substituted with a lower alkyl, (ix) a hetero ring which may be substituted with a lower alkyl, (x) R⁷R⁸N— (R⁷ and R⁸: the same or different from each other, and each represents (1) H or (2) a lower alkyl which may be substituted with an aryl or R⁹—O—CO— (R⁹: (1) H or a lower alkyl which may be substituted with an aryl), (xi) R¹⁰-T¹- (R¹⁰: (1) H, (2) a lower alkyl which may be substituted with an aryl, an HO—C₁₋₁₀ alkylene-O— or HO or (3) an aryl, T¹: O or S), or (xii) R¹¹-T²- (R¹¹: (1) OH, (2) R⁷R⁸N—, (3) a lower alkyl-O—, (4) a lower alkyl, (5) an aryl or (6) a hetero ring (T²: CO or SO₂)), further, R³, R⁴ and the adjacent C, or R⁵, R⁶ and the adjacent C, may together form a hetero ring or cyclic hydrocarbon ring, and the ring may be condensed with a benzene ring), excluding a case in which R¹ and R² in the aforementioned formula (II) are the same or different from each other, and each represents (i) H, NH₂, a cyclohexyl, phenyl which may be substituted, R^(a)—(CH₂)₂— (R^(a): HS, HO, R⁷R⁸N, COOH, an ethoxy, CN, morpholino or chloro), an alkyl which may be substituted with a substituent group of the following (a) to (e) ((a), HOOC, (b) an alkyl-O—CO—, (c) phenyl which may be substituted, (d) R⁷R⁸NCONHCO or (e) R⁷R⁸NCONHCO—), an alkenyl, phenyl-S—, phenyl-SO₂—, phenyl-NHCS— which may be substituted, phenyl-NHCO— which may be substituted, an alkyl-O—CO—, H₂NCS, chloro-COCH₂— or 1,3,4-oxadiazol-2-ylmethyl which may be substituted, or R¹, R² and the adjacent C together form pyrazol-1-yl, indol-1-yl, indazol-2-yl, piperidin-1-yl or morpholin-4-yl and R³, R⁴, R⁵ and R⁶ are the same or different from one another and each represents H, a halogen, NO₂, acetyl, HO, a lower alkyl-O—, HOOC—, a lower alkyl-O—CO—, H₂NSO₂— or a lower alkyl).
 5. A pharmaceutical composition which comprises the 2,4,6-triamino-1,3,5-triazine derivative or a pharmaceutically acceptable salt thereof described in claim
 4. 